Author: Ravi Shankar

• Deployment strengthens Plug’s growing presence across hydrogen production, refueling and industrial decarbonization projects in New Zealand and Australia
• 1 MW GenEco electrolyzer will produce hydrogen for HWR Hydrogen’s Invercargill refueling station and dual-fuel heavy transport fleet
• From distributed hydrogen production to large-scale industrial projects, Plug technology is supporting a growing range of hydrogen applications across the region

SLINGERLANDS, N.Y., Sept. 22, 2026 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced the shipment of a 1 MW GenEco™ PEM electrolyzer to HWR Hydrogen, a division of H.W. Richardson Group Limited, expanding Plug’s GenEco footprint across New Zealand and Australia.

The unit will be installed at HWR Hydrogen’s refueling station in Invercargill, New Zealand, where it will produce hydrogen to support HWR’s fleet of dual-fuel hydrogen-diesel heavy trucks.

The project represents another step in the development of New Zealand’s emerging hydrogen ecosystem, where locally produced hydrogen is increasingly being deployed to address emissions from heavy transport and other hard-to-decarbonize applications. It also builds on Plug’s existing presence in the country, including deployed electrolyzer technology supporting Hiringa Energy’s green hydrogen refueling network.

Across New Zealand and Australia, hydrogen projects are moving into real-world deployment across transportation, refueling and industrial applications, ranging from distributed production serving local demand to major industrial projects requiring hundreds of megawatts of electrolyzer capacity.

“What’s important about this project isn’t simply the size of the electrolyzer. It’s what it represents,” said José Luis Crespo, CEO of Plug. “Plug is building a strong presence alongside this emerging market, with the technology and experience to support projects at every scale. As hydrogen adoption grows across New Zealand and Australia, we’re positioned to grow with it.”

Once installed, the system will enable local hydrogen production at HWR Hydrogen’s Invercargill refueling station, supporting the company’s dual-fuel fleet while helping establish the infrastructure required for broader hydrogen adoption across Southland and the South Island.

“We’re looking forward to installing the Plug GenEco electrolyzer equipment, which we will use at our refueling station initially to supply hydrogen for Change Fuel Technologies built dual-fuel trucks operated by HWR and other customers across the Southland region. The station will also be ready to refuel OEM-supplied hydrogen vehicles for HWR companies and the wider industry as they become available,” said Gareth Wishart, GM Technology & Innovation at HWR. “Bringing Plug equipment and capabilities to Invercargill is about proving out a model we can extend across the South Island as adoption grows.”

Plug’s work with HWR adds to a growing portfolio across Australia and New Zealand. In Australia, Plug was selected to supply a 50 MW GenEco PEM electrolyzer system for Orica’s Hunter Valley Hydrogen Hub, the largest renewable hydrogen project in Australia to reach FID, which is expected to produce approximately 4,700 metric tons of renewable hydrogen annually. In New Zealand, Plug technology is already deployed to support Hiringa Energy’s green hydrogen refueling network.

About Plug Power

Plug designs, builds, and operates a fully integrated hydrogen ecosystem spanning production, storage, delivery, and power generation, enabling the global hydrogen economy. A first mover in the industry, Plug delivers electrolyzers, fuel cells, and hydrogen production plants to customers across material handling, industrial applications, and energy markets, advancing energy resilience and industrial decarbonization.

Plug’s GenEco electrolyzers span five continents, and the Company has more than 76,000 GenDrive fuel cell systems and 280+ hydrogen-powered material handling sites deployed to date. Plug also operates its own hydrogen generation network to ensure a reliable, domestically produced supply, with production facilities currently operational in Georgia, Tennessee, and Louisiana, representing a combined capacity of approximately 40 tons per day.

With employees and state-of-the-art manufacturing facilities around the world, Plug serves global leaders including Walmart, Amazon, Home Depot, BMW, and BP.

For more information, visit www.plugpower.com.

About H.W. Richardson
H.W. Richardson Group (HWR) is one of New Zealand’s largest privately owned transport companies. Headquartered in Invercargill and family owned, HWR comprises a diverse group of businesses operating across transport, petroleum, ready-mixed concrete, contracting, quarrying and technology  services in New Zealand and Australia. Building on generations of transport experience, HWR combines long-term thinking, operational capability and innovation to support its customers. HWR Hydrogen produces hydrogen for industry and is developing local production and refuelling infrastructure to support HWR businesses and other customers. Change Fuel Technologies, also part of HWR, develops hydrogen–diesel dual-fuel systems that can be retrofitted to existing diesel engines, providing a practical pathway to reduce heavy-transport emissions.

Safe Harbor

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts, including, without limitation, statements regarding the Company’s expectations, goals, plans, outlook or prospects, positive FIDs moving projects from awards to execution stage, and other statements regarding future operating results, financial condition, performance, prospects, and opportunities, are forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of management and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. These risks and uncertainties include, among other things: Whether future HWR projects reach positive FID; Whether other Plug supplied projects in Australia and New Zealand transition to execution in 2026 or beyond; Whether Plug’s first electrolyzer deployment on South Island will help establish the infrastructure required for broader hydrogen adoption across Southland and the South Island; Orica’s Hunter Valley Hydrogen Hub expected production capacity; Whether any of the projects in the global opportunity pipeline advance to execution or positive financial investment decisions; whether Plug’s industrial solutions will help reduce carbon emissions, and help make green hydrogen more cost-effective and accessible for industrial, utility, and infrastructure customers worldwide; general market, economic, competitive, and regulatory conditions; the Company’s ability to manage costs and liquidity; risks related to the Company’s future capital requirements and liquidity needs. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Plug in general, see Plug’s public filings with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of Plug’s Annual Report on Form 10-K for the year ended December 31, 2025 and Plug’s subsequent Quarterly Reports on Form 10-Q, and any other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

MEDIA CONTACT
Teal Hoyos
media@plugpower.com

Final Acceptance Certificate confirms successful completion of the one-year operational liability period

MONTREAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or the “Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today that its subsidiary Pyro Green-Gas (“PGG”), received the Final Acceptance Certificate for a previously announced major project undertaken for Tata Steel (the “Client”), one of the world’s leading diversified steel producers. The certificate confirms successful completion of the one-year operational liability period and formally transfers responsibility for future operation of the system to the Client.

“The Final Acceptance Certificate announced today marks the culmination of years of close collaboration with Tata Steel to develop and implement a solution for one of its largest steelmaking facilities,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “The steel industry’s off-gas processing sector has traditionally been dominated by some of the world’s largest engineering firms, making the successful completion and final acceptance of a system of this scale particularly significant for PyroGenesis. The system installed for Tata Steel covers an area equivalent to a football field and spans the height of a five-storey building. Having demonstrated our technology and engineering capabilities at this scale, we are now attracting interest from other major steelmakers. With more than 1,400 blast furnaces installed across 477 plants in 55 countries¹ and continued investment in blast-furnace steelmaking – with approximately 70% of planned new global steel projects expected to incorporate blast furnaces² – we believe there is a significant market opportunity for our advanced coke-oven gas cleaning and other steel industry technologies.”

About the Final Acceptance Certificate

As announced on July 15, 2025, PGG completed a major project for Tata Steel to develop and supply coke-oven gas purification solutions and hydrogen production processes designed to separate and recover hydrogen while removing toxic contaminants from coke oven gas. Under the terms of the agreement, PGG successfully passed all required project milestones. These milestones included (i) an Integrated Cold Test, which confirmed that all equipment and components met or exceeded the required operating and safety standards, and (ii) a Provisional Acceptance Test, which verified that the systems met agreed-upon contractual specifications.

The project completion announced in July 2025 initiated a one-year compliance and defects liability period during which system performance was monitored and PGG remained responsible for addressing any operational deficiencies. Such periods are standard for industrial projects of this scale. Generally, following the conclusion of such one-year period, a client may either extend the evaluation period or issue final acceptance, thereby assuming responsibility for future operations. Tata Steel has now issued the signed Final Acceptance Certificate, confirming completion of PGG’s work under the agreement and the transfer of responsibility for future operations of the system to Tata Steel. 

Image: PyroGenesis’ Coke Oven Gas and Hydrogen Extraction System at Tata Steel, Kalinganagar, India

About the Tata Steel Coke-Oven Gas Valorization and Hydrogen Production Project

Blast furnaces utilize coking coal, or “coke”, as part of the process to transform iron ore into steel. Coke acts as both a fuel to generate the intense heat required for smelting and as a reducing agent to remove oxygen from the iron ore. The gas released during the coke production process, known as coke-oven gas, is a toxic mix of human carcinogens comprised of approximately 54% hydrogen with the balance consisting of methane, carbon monoxide, carbon dioxide, tar, naphthalene, and other hydrocarbons which must be separated and removed before the hydrogen can be cleaned, reformed, and reused³. PyroGenesis’ subsidiary Pyro Green-Gas has decades of experience designing and installing technology solutions specifically for these situations.

As stated above, PGG supplied both coke-oven gas purification solutions and hydrogen production processes geared to extract hydrogen and other toxic gases from the blast furnace process. The gases were then separated, cleaned, and processed to render hydrogen to a 99.999% purity level. The plant has been in continuous 24 hrs./day operation at the Tata steel facility in Kalinganagar, India, where the newly reformed hydrogen produced by the system is being reused in other applications at the facility, thereby improving production efficiency and environmental outcomes. The systems installed by PGG are purifying 32,000 cubic meters of coke-oven gas per hour while extracting 620 cubic meters of ready-to-use hydrogen per hour.

About Pyro Green-Gas Inc.

Pyro Green-Gas offers technologies, equipment, and expertise in biogas upgrading and air pollution controls. Pyro Green-Gas designs and builds: (i) gas upgrading systems to convert biogas to renewable natural gas (RNG); (ii) pyrolysis-gas purification; (iii) biogas & landfill-gas flares and thermal oxidizers; and (iv) purification of coke-oven gas (a by-product in the primary steel industry arising from the conversion of coal into coke) into high purity hydrogen, which is in high demand across the industry. In addition, Pyro Green-Gas produces a line of landfill gas flares which reduce greenhouse gas emissions from landfills, and is actively involved in gas purification and separation, and reforming and synthesis of hydrocarbon gases, as well as waste gas and solid waste valorization systems.

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

Cautionary and Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under “Risk Factors” in PyroGenesis’ latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis’ profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.

For further information contact ir@pyrogenesis.com or visit http://www.pyrogenesis.com

_______________________________
¹ https://www.steeltimesint.com/news/blast-furnace-tracker-offers-first-free-global-coverage-of-blast-furnaces

² https://www.energymonitor.ai/sectors/industry/weekly-data-70-of-planned-steel-production-projects-are-dirty-blast-furnaces/

³ https://www.ncbi.nlm.nih.gov/books/NBK590934/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4304e9f9-1d83-4172-bcb3-4e890e03f339

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients

Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa

JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s (“Santen”) Ryjunea® from Sydnexis, Inc. (“Sydnexis”) for a $23 million upfront payment.

Ryjunea is a once-nightly, low-dose atropine eye drop designed to slow progression of myopia (commonly known as nearsightedness) in pediatric patients. Treatment may be indicated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. The product uses a standardized 0.01% formulation of atropine with deuterated water designed to improve efficacy, comfort, and stability in the pediatric population. Santen licensed rights to Ryjunea in Europe, the Middle East, and Africa (“EMEA”) from Sydnexis in 2021. Ryjunea was approved by the European Commission in June 2025 and the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) in October 2025.

“Ryjunea represents the type of differentiated asset we look to add to our expanding royalty portfolio. As the first and only approved pharmacological treatment in the European Union and the United Kingdom for slowing pediatric myopia, Ryjunea addresses a significant market need by providing a stable, clinically validated, and GMP manufactured option to manage this chronic condition. Santen has built a strong ophthalmology presence across Europe and has identified myopia as a key strategic growth area, giving us confidence in the product’s long-term commercial potential,” said Todd Davis, CEO of Ligand.

Under the terms of the agreement, Ligand will pay $23 million upfront to acquire a 100% interest in certain payments and related rights under Sydnexis’s existing license agreement with Santen. The acquired payment rights include a tiered low-double-digit to high-teens royalty on Ryjunea net sales in EMEA, as well as certain milestone payments. Sydnexis retains commercial rights to Ryjunea in the U.S. and all other non-Santen licensed territories.

Myopia is a condition in which the focal point for distant objects is in front of the retina, instead of directly on it, and results in vision loss. It has been reported that, in addition to affecting patient quality of life, the progression to “high myopia” increases the risk of severe ocular complications that can lead to permanent visual impairment or blindness. In Europe, approximately 1 in 3 children and adolescents are projected to be affected by myopia by 2050,¹ and Santen estimates 14 million patients were affected in 2025.²

McDermott Will & Schulte LLP and Cooley LLP served as legal advisors to Ligand.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to Ryjunea’s commercial potential; the size and growth of the market for treatments for pediatric myopia; Santen’s commercialization, market access and other activities relating to Ryjunea; future sales of Ryjunea; Ligand’s expected receipt of royalties, reimbursement approval milestones and sales milestones relating to Ryjunea and Ligand’s royalty portfolio strategy and expected revenue characteristics.

These statements are based on various assumptions and on the current expectations of Ligand’s management and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, many of which are beyond Ligand’s control. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, Ligand’s reliance on Santen and other third parties for the commercialization, manufacture and sale of Ryjunea and for the payment of royalties and milestones; the possibility that Ryjunea sales may be lower than expected; the timing, availability and scope of regulatory, pricing and reimbursement approvals; competition from compounded atropine, optical treatments and existing or future pharmaceutical products; changes in market acceptance, prescribing practices or treatment guidelines; the possibility that applicable royalty rates may be reduced under the underlying license agreement; challenges to, or the expiration or invalidation of, intellectual property rights relating to Ryjunea; and the other risk factors discussed under the heading “Item 1A. Risk Factors” in the Ligand’s Annual Report on Form 10-K for the year ended December 31, 2025 (filed February 27, 2026) and Quarterly Reports on Form 10-Q for the quarter ended March 31, 2026 (filed with the SEC on May 8, 2026) and for the quarter ended June 30, 2026 (filed with the SEC on August 7, 2026). Ligand cautions against placing undue reliance on these forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update any forward-looking statements except as required by law.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

---

¹ Liang J, et al. Br J Ophthalmol. 2024; bjo–2024–325427.
² Santen Pharmaceutical Co., Ltd., Santen Report 2025. https://www.santen.com/content/dam/santen/global/pdf/en/ir/document/202503/ar2025e.pdf

Company Highlights Expanding Patent Portfolio and Competitive Position While Advancing Texatron™ Testing and Preparing for Potential Uplisting to a National Securities Exchange

SOUTHLAKE, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — American Fusion Inc. (OTCQB: AMFN) (“American Fusion” or the “Company”), a developer of advanced fusion-energy technology, today provided a comprehensive corporate update addressing the continued expansion and protection of its intellectual property portfolio, the Company’s progress as a public company, continued testing and validation of the Texatron™ platform, and its pathway toward a potential uplisting to a national securities exchange.

Protecting the Texatron™ Intellectual Property Portfolio

American Fusion reported the filing of 21 additional U.S. patent applications, bringing the Company’s intellectual property portfolio to 151 pending U.S. patent applications.

The newly filed applications continue the Company’s strategy of building multiple layers of intellectual property protection around the Texatron™ platform, including its core architecture as well as alternative configurations, materials, geometries, components, operating systems and methods that may become increasingly important as the technology advances.

131. U.S. Patent Application No. 19/802,584 — Aluminum Unitary Fusion System with Rifled Toroidal Interior Chamber and Pulsed Electrical Energy

132. U.S. Patent Application No. 19/802,608 — Quartz Clamshell Fusion Confinement Device with Rifled Toroidal Interior Chamber and Electromagnetic Foil

133. U.S. Patent Application No. 19/804,026 — Unitary Quartz Fusion Confinement Device with Rifled Toroidal Interior Chamber and Electromagnetic Foil

134. U.S. Patent Application No. 19/804,057 — Quartz Clamshell Experimental Fusion System with Electrically Generated Electromagnetic Foil Along Rifling

135. U.S. Patent Application No. 19/804,074 — Quartz Unitary Experimental Fusion System with Electrically Generated Electromagnetic Foil Along Rifling

136. U.S. Patent Application No. 19/808,626 — Quartz Clamshell Fusion Confinement System with Helium-3/Deuterium Fuel Injection and Electromagnetic Foil

137. U.S. Patent Application No. 19/805,591 — Quartz Unitary Fusion Confinement System with Helium-3/Deuterium Fuel Injection and Electromagnetic Foil

138. U.S. Patent Application No. 19/805,590 — Quartz Nuclear Fusion Reactor with Rifled Toroidal Interior Chamber and Ridge-Mounted Coil

139. U.S. Patent Application No. 19/805,593 — Nuclear Fusion Reactor with Unitary Quartz Confinement Device and Ridge-Mounted Coil

140. U.S. Patent Application No. 19/805,596 — Clamshell Quartz Fusion Confinement Device with Helium-3/Deuterium Fuel Injection and Ridge-Mounted Coil

141. U.S. Patent Application No. 19/805,599 — Unitary Quartz Fusion Confinement Device with Helium-3/Deuterium Fuel Injection and Ridge-Mounted Coil

142. U.S. Patent Application No. 19/808,629 — Quartz Clamshell Fusion System with Rifled Toroidal Chamber and Ridge-Mounted Coil

143. U.S. Patent Application No. 19/808,632 — Quartz Unitary Fusion System with Rifled Toroidal Chamber and Ridge-Mounted Coil

144. U.S. Patent Application No. 19/808,644 — Symmetrical Two-Half-Shell Quartz Fusion Confinement Device with Rifled Toroidal Chamber and Helium-3/Deuterium Fuel Injection

145. U.S. Patent Application No. 19/808,653 — Symmetrical Unitary Quartz Fusion Confinement Device with Rifled Toroidal Chamber and Helium-3/Deuterium Fuel Injection

146. U.S. Patent Application No. 19/811,469 — Symmetrical Quartz First and Second Half-Shell Apparatus with Rifled Toroidal Chamber and Equal Helium-3/Deuterium Fuel Injection

147. U.S. Patent Application No. 19/811,472 — Geometrically Symmetrical Unitary Quartz Confinement Apparatus with Approximately Equal Helium-3/Deuterium Fuel Injection

148. U.S. Patent Application No. 19/811,476 — Symmetrical Quartz First and Second Hemisphere Fusion System Forming a Rifled Toroidal Interior Chamber

149. U.S. Patent Application No. 19/813,120 — Symmetrical Unitary Quartz Fusion Housing Forming a Rifled Toroidal Interior Chamber

150. U.S. Patent Application No. 19/813,122 — Asymmetrical Unequal Two-Shell Quartz Fusion System Forming a Rifled Toroidal Interior Chamber

151. U.S. Patent Application No. 19/813,124 — Asymmetrical Unitary Quartz Fusion Containment Device Forming a Rifled Toroidal Interior Chamber

American Fusion believes the importance of this strategy extends considerably beyond the number of patent applications filed. The commercial fusion industry is attracting substantial investment, but even some of the industry’s most heavily funded participants are now publicly discussing timelines extending into 2029 and 2030 for full operation of planned commercial fusion power facilities. American Fusion believes the Texatron™ platform may offer a materially shorter pathway to commercialization, although significant testing, validation and engineering work remains and there can be no assurance that the Company will achieve its targeted timeline.

Management believes this potential time-to-market advantage substantially increases the importance of protecting the Company’s intellectual property. As the Texatron™ advances, American Fusion is attracting increasing attention from within the fusion industry, prospective commercial counterparties, investors and others seeking greater information regarding the technology and its underlying engineering. The Company believes that protecting inventions, designs, configurations, components and methods before providing detailed technical disclosure is essential to preserving its potential competitive advantage.

American Fusion intends to continue providing shareholders with meaningful and timely information regarding the Company’s progress. At the same time, management believes transparency must be balanced against the obligation to protect proprietary information that could have substantial commercial value. The Company does not intend to disclose technical information simply to satisfy outside interest when doing so could compromise intellectual property or provide competitors with insight into the Texatron™ platform before appropriate protections are in place.

Brent Nelson, Executive Chairman of American Fusion, commented: “The fusion industry is moving toward commercialization, but the timelines being discussed by other major participants increasingly extend toward the end of this decade. We believe the Texatron™ may provide us with an opportunity to move considerably faster. If we are right, protecting the technology becomes even more important. We are not going to sacrifice a potential competitive advantage simply to disclose engineering details before the underlying intellectual property has been appropriately protected.”

Nelson continued: “Our intellectual property strategy is designed to protect not merely a single fusion device, but a family of Texatron™ Fusion Engines™ and the technologies that may support multiple sizes, configurations, applications and future generations of the platform. We believe that intellectual property may ultimately represent one of American Fusion’s most important long-term corporate assets.”

Patent applications remain subject to examination by the U.S. Patent and Trademark Office, and there can be no assurance that any particular application will result in an issued patent or that any patent ultimately issued will provide commercially meaningful protection.

Texatron™ Testing and Development Infrastructure

American Fusion continues to pursue additional testing of the Texatron™️ platform at a local university facility while advancing plans for a dedicated, Company-controlled testing facility.

The Company believes establishing its own testing infrastructure is an important next step in the Texatron™️ development program. A dedicated facility would give American Fusion greater control over testing schedules, equipment configuration, diagnostic instrumentation and engineering workflows, and would allow the Company to conduct testing without many of the scheduling and operational constraints inherent in performing advanced research within third-party facilities.

American Fusion has identified a site for the facility and has negotiated the principal terms and purchase price. The Company expects to enter escrow on the property through its affiliate. Completion of the transaction remains subject to customary closing conditions, and there can be no assurance that it will close on the anticipated terms or at all. The Company will file additional details with the Securities and Exchange Commission on a Current Report on Form 8-K, as required.

The dedicated facility is intended to complement, rather than replace, the work already performed through the Company’s university and third-party relationships. American Fusion expects outside scientific, engineering and institutional resources to remain important components of its broader validation program.

“As the Texatron™️ program advances, we need the ability to test when the engineering requires it, rather than only when a third-party facility is available,” said Brent Nelson. “Securing our own testing facility will give our scientific and engineering teams considerably greater control over the pace and sequencing of the program, while allowing us to configure the equipment and diagnostics specifically around the Texatron™️.”

The Texatron™️ Fusion Engine™️ continues to undergo testing and engineering validation.

Pathway Toward a National Exchange Uplisting

American Fusion is advancing preparations for a potential uplisting of its common stock from the OTCQB to a national securities exchange.

The Company has been evaluating the Texas Stock Exchange (“TXSE”) as its preferred potential venue, while also evaluating the New York Stock Exchange (“NYSE”) and Nasdaq as alternative venues. Based on its evaluation to date, American Fusion believes TXSE represents a particularly compelling option given the Company’s Texas domicile, its Texas headquarters and the substantial engineering and development work it conducts within the state. The Company has not made a final venue determination and intends to select the exchange it believes will provide the strongest long-term platform for American Fusion and its shareholders.

Based on its review to date, the Company believes it currently satisfies TXSE’s initial listing criteria other than the minimum bid-price requirement. American Fusion believes it may be eligible to list under TXSE’s $200 million market-capitalization standard based on its current valuation. With respect to the minimum bid-price requirement, the Company will evaluate, based on the trading price of its common stock at the time of the proposed uplisting, whether a reverse stock split would be necessary to meet that requirement.

TXSE’s rules provide for a confidential pre-application eligibility review before a prospective issuer submits an original listing application. Upon successful completion of that review, TXSE may issue a clearance letter permitting an eligible company to proceed with a formal listing application. American Fusion, together with its securities and capital markets advisors, is preparing to position the Company for that process.

The Company believes much of the infrastructure required for a national-exchange listing was put in place through the work completed during 2026, including audited financial statements, SEC reporting status, current periodic reporting, improved quotation infrastructure, OTCQB qualification and the continued development of its board and corporate-governance structure. American Fusion continues to evaluate the remaining requirements and available qualification pathways, as well as potential capital-markets transactions that could accompany an uplisting.

The Company has also received several financing term sheets from various funds contemplating potential capital in connection with a national-exchange uplisting, along with additional funding intended to accelerate commercialization of the Texatron™️ platform. American Fusion is evaluating these proposals alongside other potential financing alternatives. No definitive financing agreement has been executed, and there can be no assurance that any proposed financing will be completed or, if completed, on what terms.

American Fusion has been invited to visit the New York Stock Exchange, where Chief Executive Officer Brent Nelson and members of the management team will participate in an interview with New to The Street, filmed on the floor of the exchange on Monday, September 28, 2026, to provide an update on the Company. New to the Street is a national TV broadcasts on Bloomberg TV and FOX Business. While in New York, management will also meet with several banks and institutional investors that have expressed interest in the Company.

“OTCQB was never intended to be the final destination for American Fusion,” said Brent Nelson. “It was an important step in building the reporting, governance and market infrastructure required for where we intend to take the Company. We are now working through the requirements and available pathways for a potential national-exchange uplisting.”

Nelson continued, “TXSE is particularly interesting to us. American Fusion is a Texas company developing advanced energy technology in Texas, the energy capital of the United States, and we believe there is a natural alignment with a national securities exchange headquartered here. We are also evaluating the NYSE and Nasdaq, and will ultimately pursue the venue and structure that we believe best positions American Fusion for its next stage of development and commercialization.”

Any potential national-exchange uplisting remains subject to the satisfaction of all applicable listing requirements, completion of the applicable exchange review process, market conditions and approval by the selected exchange. The Company’s belief regarding its eligibility is based on its own assessment and has not been confirmed by TXSE. There can be no assurance that American Fusion will qualify for or complete an uplisting to TXSE, NYSE, Nasdaq or any other national securities exchange, or that any reverse stock split, if effected, would enable the Company to meet or maintain applicable listing requirements.

About American Fusion Inc.

American Fusion Inc. (OTCQB: AMFN) is an advanced energy platform company focused on the development and commercialization of next-generation fusion energy technologies. The Company is advancing the Texatron™ Fusion Engine™ aneutronic fusion platform, designed for modular, infrastructure-grade deployment across industrial, commercial, defense and grid-constrained applications.

The Company’s development strategy emphasizes system-level engineering, disciplined intellectual-property protection and scalable architectures intended to support long-term commercial operation, while maintaining a focus on capital discipline and transparent corporate governance.

For more information about American Fusion and its Texatron™ platform, please visit: americanfusionenergy.com

For an overview of American Fusion, please click here: American Fusion Overview

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and the future performance of American Fusion Inc., including statements regarding American Fusion’s intellectual property portfolio and pending and future patent applications; the development, testing, validation, anticipated performance, scalability and potential applications of the Texatron™ Fusion Engine™; commercialization, manufacturing, financing, strategic partnerships, regulatory approvals and customer opportunities; the Company’s evaluation of a potential listing on the Texas Stock Exchange; satisfaction of applicable listing standards and completion of any related corporate or capital-markets actions; and other future business operations. Words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Patent applications are subject to examination and there can be no assurance that any application will result in an issued or commercially valuable patent. The developed Texatron™ Fusion Engine™ is undergoing testing and continued engineering validation and has not demonstrated sustained net electricity generation from a commercial system. There can be no assurance that the Company will achieve its scientific, engineering, regulatory, financing, manufacturing or commercialization objectives, satisfy the applicable initial listing standards of TXSE, receive approval to list its common stock on TXSE or complete any potential listing. This press release does not constitute an offer to sell or solicitation of an offer to purchase securities. Readers should not place undue reliance on forward-looking statements, and American Fusion undertakes no obligation to update them except as required by law.

Corporate Communications

833-872-2636 ext. 730
ir@americanfusionenergy.com
info@americanfusionenergy.com
americanfusionenergy.com

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR”, the “Company” or “Premier American Uranium”) (TSXV: PUR) (OTCQB: PAUIF) announces that Mr. Tim Rotolo has resigned as Chairman and a director of the Company, effective September 21, 2026. Michael Harrison, a current director of PUR, has been appointed Chairman of the Board.

Mr. Rotolo has played an important leadership role in PUR since its formation in late 2023, initially serving as the Company’s Chief Executive Officer before transitioning to Chairman in March 2024. During his tenure, PUR significantly expanded its U.S. uranium portfolio through the acquisitions of American Future Fuel Corporation and Nuclear Fuels Inc. and recently announced a strategic transaction with DISA Uranium Corporation. Mr. Rotolo indicated that his decision follows the achievement of an important milestone in the strategy Sachem Cove helped establish for PUR: building a meaningful U.S. uranium platform and attracting a strategic partner capable of supporting its next phase of growth. The Company’s recently announced transaction with DISA Uranium represents the realization of that strategy.

Colin Healey, Chief Executive Officer of PUR, commented, “On behalf of the Board and management team, I would like to thank Tim for his leadership and significant contributions to PUR. From serving as PUR’s first CEO to guiding the Company as Chairman, Tim has been instrumental in building the business and establishing the foundation we have today. We are pleased that Sachem Cove will remain PUR’s largest shareholder and continue to support the Company as we enter our next phase of growth.”

Tim Rotolo, commented, “When Sachem Cove backed PUR, our thesis was that a disciplined consolidator with the right team could build a meaningful U.S. uranium platform and attract the type of strategic partner capable of accelerating its development. The recent transaction with DISA Uranium represents the realization of that thesis and positions PUR exceptionally well for its next chapter. With that strategic relationship now in place, I believe this is the right time for me to step away from the Board and focus on Sachem Cove’s other commitments. I am proud of what the team has accomplished since PUR’s formation and confident in its ability to execute the strategy from here. Sachem Cove remains PUR’s largest shareholder, and we look forward to continuing to support the Company from the shareholder side.”

Mr. Harrison has served as a director of PUR since its formation and brings more than 30 years of mining, capital markets and transaction experience. As Managing Partner of Sprott Streaming and Royalty, he has extensive experience financing and advising mining companies, including uranium developers. His uranium-sector experience includes the merger of Denison Mines Inc. and International Uranium Corporation, the initial public offering of Virginia Uranium Inc., and prior directorships with Uranium Royalty Corp. and Macusani Yellowcake Inc.

Michael Harrison, Chairman, commented, “I am pleased to assume the role of Chairman at an important point in PUR’s development. The Company has assembled a strong portfolio across several leading U.S. uranium districts, and the strategic relationship with DISA Uranium provides additional financial and technical support as PUR advances its core assets. I look forward to working with the Board and management team to build on this foundation. I would also like to thank Tim for his leadership and the important role he has played in establishing PUR.”

About Premier American Uranium Inc.

Premier American Uranium is focused on consolidating, exploring, and developing uranium projects across the United States to strengthen domestic energy security and advance the transition to clean energy. The Company’s extensive land position spans five of the nation’s top uranium districts, with active work programs underway in New Mexico’s Grants Mineral Belt and Wyoming’s Great Divide and Powder River Basins.

Backed by strategic partners including Sachem Cove Partners, IsoEnergy Ltd., Mega Uranium Ltd., and other leading institutional investors, PUR is advancing a portfolio supported by defined resources and high-priority exploration and development targets. Led by a distinguished team with deep expertise in uranium exploration, development, permitting, operations, and uranium-focused M&A, the Company is well positioned as a key player in advancing the U.S. uranium sector.

For More Information, Please Contact:

Premier American Uranium Inc.
Colin Healey, CEO

info@premierur.com
Toll-Free: 1-833-223-4673
Twitter: @PremierAUranium
www.premierur.com

Neither TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements with respect to, planned activities including the closing of the transaction with DISA Uranium and the benefits thereof; and other activities, events or developments that are expected, anticipated or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

Forward-looking information and statements are based on our current expectations, beliefs, assumptions, estimates and forecasts about PUR’s business and the industry and markets in which it operates. Such forward-information and statements are based on numerous assumptions, including among others, that the transaction with DISA Uranium will be completed and that the benefits of the strategic transaction with DISA Uranium will be achieved, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms, that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Company’s planned exploration activities will be available on reasonable terms and in a timely manner. Although the assumptions made by PUR in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate.

Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual results, performances and achievements of Premier American Uranium to differ materially from any projections of results, performances and achievements of Premier American Uranium expressed or implied by such forward-looking information or statements, including, among others: that the transaction with DISA Uranium may not be completed and that the benefits thereof may not be realized, the limited operating history of the Company, negative operating cash flow and dependence on third party financing, uncertainty of additional financing, delays or failure to obtain required permits and regulatory approvals, changes in mineral resources, no known mineral reserves, aboriginal title and consultation issues, reliance on key management and other personnel; potential downturns in economic conditions; availability of third party contractors; availability of equipment and supplies; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; changes in laws and regulation, competition, and uninsurable risks and the risk factors with respect to Premier American Uranium set out in PUR’s annual information form for the year ended December 31, 2024 and the other documents of PUR filed with the Canadian securities regulators and available under PUR’s profile on SEDAR+ at www.sedarplus.ca.

Although PUR has attempted to identify important factors that could cause actual actions, events or results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. PUR undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities law.

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain 

Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease

SUNRISE-FA 2 pivotal study continues enrollment and remains the company’s top priority development program; topline data on track for 2H 2027

Disciplined capital allocation supports these strategic initiatives while maintaining cash runway into 2028

Company to host webcast today at 8:00 AM ET

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire Mantle Therapeutics Inc. and three new research collaborations supporting cerebellar-targeted development opportunities for frataxin gene therapy. Together, these transactions will simultaneously expand Lexeo’s vision and capabilities beyond gene therapy, deepen the company’s focus on the multisystem burden of FA, and add multiple therapeutic approaches designed to increase or restore frataxin in the brain. These transactions are being pursued within Lexeo’s existing balance sheet capacity, with cash runway guidance unchanged into 2028 and future investment decisions guided by predefined milestones to identify and prioritize the most compelling central nervous system (CNS) opportunities.

“Our objective is to build the best-in-class therapeutic platform for the treatment of Friedreich ataxia,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “LX2006 remains our highest priority as the best-in-class treatment for FA cardiomyopathy, and the addition of Mantle’s pipeline, combined with new research collaborations will broaden our technology platform with multiple complementary CNS-targeted therapeutic strategies designed to restore frataxin in the brain and further improve outcomes for individuals living with FA. Together, these initiatives will strengthen our leadership position in the disease category while supporting disciplined portfolio advancement and capital allocation.”

Acquisition of Mantle Therapeutics Will Establish Lexeo’s Multimodal Friedreich Ataxia Platform

On September 16^th, 2026, Lexeo entered into an agreement to acquire Mantle Therapeutics Inc. (“Mantle”), a private clinical stage company focused on developing multiple therapies for the treatment of FA. The acquisition will deepen Lexeo’s focus on FA and strengthen its capabilities in addressing the neurologic aspects of disease.

The acquired portfolio will include:

• LX3010 (MTL-104): a clinical stage, oral combination therapy designed to increase frataxin expression while addressing mitochondrial function and oxidative stress through complementary mechanisms (HDAC inhibition and NRf2). Early clinical data includes an approximately 6-point improvement in mFARS scores at 16 weeks and a mean nine-fold increase in frataxin protein levels from baseline in muscle biopsies across 11 FA patients.
• LX3030 (MTL-707): a pre-clinical stage oral, tissue-penetrant true small molecule (sub-500Da) designed to increase production of endogenous frataxin in the central nervous system. LX3030 is a third-generation benzamide HDAC inhibitor that builds on published clinical work demonstrating oral benzamide HDACs increase frataxin in FA patients by epigenetic modulation and acetylation of chromatin. Preclinical studies of LX3030 have demonstrated robust increases in frataxin, supporting continued evaluation of LX3030 as a differentiated oral therapy.
• LX3050 (MTL-501): a pre-clinical stage recombinant human frataxin fused to a proprietary anti-TfR1 Fab, intended to directly replace the deficient frataxin protein and utilize a TfR1-targeting brain shuttle designed to cross the blood-brain barrier and increase delivery of frataxin to the brain. In vitro studies have demonstrated dose-responsive improvements in measures of mitochondrial function, providing early support for the program’s proposed mechanism.
• LX3070 (MTL-801): a discovery stage ASO Fab conjugate program designed to stabilize FXN mRNA and thereby increase translation of endogenous frataxin protein. The program combines an RNA-targeted mechanism conjugated to a proprietary anti-TfR1 Fab. In vitro studies have demonstrated dose-responsive increases in frataxin.

Under the terms of the agreement, Lexeo will pay Mantle shareholders $8.3 million in upfront consideration, consisting of a combination of cash and equity. The agreement also provides for up to $13.0 million in success-based milestone payments, payable in a combination of cash and equity upon the achievement of future clinical and regulatory milestones, bringing the total potential consideration to $21.3 million. Subject to customary closing conditions, the transaction is expected to close in the third quarter of 2026.

Following closing, Lexeo will continue its evaluation of the acquired programs against predefined scientific, clinical, strategic and financial criteria and will prioritize investment in the opportunities demonstrating the strongest potential for clinical patient impact, regulatory success and shareholder value creation. The Company’s cash runway guidance into 2028 includes plans to advance one of the acquired programs into clinical development. The Company expects to provide a program prioritization update in early 2027 and submit an IND for its next FA development candidate in 2027.

Together with LX2006, the expanded portfolio provides Lexeo with the technology to evaluate multiple biologic theses for the treatment of FA in the brain. These complementary therapies will be evaluated both as standalone treatments and in concert with LX2006, and all future clinical trials are expected to include a treatment arm for patients previously treated with LX2006.
  
Strategic Collaborations Supporting Sequential Dosing of CNS Targeted Frataxin Gene Therapy

Lexeo has established three collaborations to evaluate cerebellar-targeted sequential dosing of frataxin gene therapy, all designed to be complementary to systemically administered LX2006.

• Weill Cornell Medicine Cerebellar-Targeted Sequential Dosing Research: Lexeo entered into a Sponsored Research Agreement with Weill Cornell Medicine to evaluate intra-cisternal administration of LX2006 following systemic dosing in large animal models. The collaboration is intended to further the understanding and translation of cerebellar-targeted sequential dosing, and to evaluate dosing parameters and immune-suppression strategies that may support repeat administration.
• Vivet Therapeutics IgG-Degrading VTX-PID Enzyme Option Agreement: Lexeo entered into an option agreement with Vivet Therapeutics providing the opportunity to secure an exclusive license to VTX-PID, an IgG-degrading enzyme intended to support immune-suppression strategies that may expand treatable population with immunization against AAV and facilitate repeat administration of LX2006.
• Apertura Gene Therapy Novel CNS Capsid (CapX) Option Agreement: Lexeo entered into an option agreement with Apertura Gene Therapy providing the opportunity to secure a license to a novel, intravenously administered, blood-brain barrier-crossing capsid that is expected to enable a less invasive route of administration to the CNS following initial systemic administration of LX2006.

Similarly, Lexeo intends to evaluate the outcomes of these research collaborations against predefined scientific, clinical and financial criteria and prioritize investment in opportunities with the greatest potential to advance into clinical development and provide FA patients with a sequential CNS-dosing option to complement prior systemic administration of LX2006.

Expanded Vision to Reflect Strategic Focus

Lexeo is introducing an expanded vision reflecting the company’s focus on the treatment of genetic diseases with high unmet need in both the cardiovascular and neurological space. The refreshed positioning aligns with Lexeo’s growing Friedreich ataxia platform and expanded portfolio across multiple modalities outside of gene therapy.

Continued Advancement of LX2006

LX2006 continues to advance enrollment in the SUNRISE-FA 2 pivotal study, which remains Lexeo’s highest operational and capital-allocation priority. The program remains on track to provide a topline data readout in the second half of 2027. The Company believes LX2006 has the potential to become the first disease-modifying therapy specifically targeting Friedreich ataxia cardiomyopathy.

Corporate Webcast Details
Lexeo Therapeutics will host a webcast at 8:00 AM ET today, September 22, 2026. Analysts and investors can participate by accessing the webcast live on the Events & Presentations page in the Investors section of Lexeo’s website, www.lexeotx.com. The webcast will be archived on the company’s website following the call.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory developments, trial design changes and approval, expectations regarding the time period over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo’s financial condition, the expected closing of the proposed acquisition of Mantle Therapeutics Inc. and the satisfaction of the conditions thereto, the anticipated benefits of the proposed acquisition and the acquired programs, the timing and outcome of Lexeo’s evaluation of the acquired programs and research collaborations against predefined criteria, the expected timing of a program prioritization update, the expected submission of an IND for Lexeo’s next Friedreich ataxia development candidate, and the potential achievement of future clinical and regulatory milestones. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Media Response:
Media@lexeotx.com

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com

BROOMFIELD, Colo., Sept. 22, 2026 (GLOBE NEWSWIRE) — Gogo Special Missions, the military/government division of Gogo (NASDAQ: GOGO), and Insitu, a Boeing company, announced today the successful completion of testing and integration of a new, modified high-speed satellite connectivity solution, tailored specifically for Group 3 Uncrewed Aerial Systems (UAS). The leading Group 3 UAS OEM and the leading Global UAS connectivity supplier have partnered to optimize the Gogo Galileo HDX antenna for installation on Insitu’s Integrator UAS.

“The Integrator UAS offers theater-level range and capacity for multiple customer payloads. Adding an ITAR-free, high-speed SATCOM option is an essential capability for our global customers—extending command and control and allowing seamless backhaul of sensor data with minimal latency. We are pleased to partner with Gogo, which will deliver a turnkey solution that includes UAS equipment, satellite services, and 24/7 support,” says John Kelly, Vice President of Growth of Insitu.

“The collaboration with Insitu is particularly exciting, as it gives us the opportunity to modify our proven HDX solution, specifically to address the fast-growing Group 3 UAS market,” explains Ben Massey, Senior Vice-President & General Manager of Gogo Special Missions. “With our antenna system further optimized for size and weight, Insitu customers will now be able to access high-speed, global internet over Eutelsat’s OneWeb LEO satellite constellation, with a single line replaceable unit (LRU) configuration.”

The two companies successfully completed integration and testing of the customized Gogo Galileo HDX on the Integrator this month, alongside the FLARES Vertical Take-off and Landing kit. This new capability requires minimal deck space, can launch in high seas and gusty winds, and requires zero aircraft modifications.

Photo caption: Gogo Special Missions and Insitu have successfully completed testing and integration of a new, modified high-speed satellite connectivity solution tailored specifically for Group 3 Uncrewed Aerial Systems (UAS).

About Gogo

Gogo has been the trusted connectivity infrastructure partner for military and government operations and business aviation for three decades. Rather than promoting a single network or technology, Gogo Special Missions has a network-neutral approach, helping military and government customers navigate an increasingly complex communications landscape by combining deep market knowledge and global aviation expertise to identify, integrate and support the connectivity solution best suited to each mission and operational requirement.

Providing access to a complete connectivity ecosystem through a single trusted partner, Gogo Special Missions offers onboard hardware, software, air-to-ground and multi-orbit, multi-band satellite connectivity, service plans, and 24/7/365 multilingual customer support. The company’s interoperable solutions securely connect crewed and uncrewed aircraft across the operational theatre, enabling seamless communications in any mission environment. Dedicated to customer success, Gogo Special Missions delivers the flexibility, resilience and choice customers need while ensuring predictable pricing and future-proof technology.

From ISR and command-and-control missions to executive transport, humanitarian operations and emergency response, Gogo delivers secure, reliable, mission-critical connectivity that enables customers to execute every mission with confidence.

About Insitu

Boeing subsidiary Insitu is a pioneer in the design, development, production, and operation of high-performance, cost-effective, resilient, VTOL-capable UAS and AI-enabled software solutions. Insitu’s technologies have helped the armed forces of 35 nations make quicker, more informed decisions to bring warfighters home safely.

With offices in the US, Australia, the UK, and the UAE, Insitu has manufactured and fielded more than 3,500 UAS and provides operations and support networks in every hemisphere of the globe. Learn more at Insitu.com.

Media contacts

Caroline Phaneuf – Arena Group         
Caroline@arenagroupassociates.com                                
+1 514 778 5092                                

Stacey Giglio         
sgiglio@gogoair.com                 
+1 321 361 6101

Cautionary Note Regarding Forward-Looking Statements

Certain disclosures in this press release and related comments by our management include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding our business outlook, industry, business strategy, plans, goals and expectations concerning our market position, international expansion, future technologies, future operations, margins, profitability, future efficiencies, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release. Forward-looking statements are based on our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to have been correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, the following: our ability to continue to generate revenue from the provision of our connectivity and other service offerings; our development and fixed-price contracts; our reliance on our key OEMs and dealers for equipment sales; our dependence on single-source, third party satellite network providers; the impact of competition; our ability to maintain high-quality customer support; our reliance on third parties for equipment components and services; our participation in U.S. government contracts; our participation in non-U.S. government contracts; the finite useful life of satellites; the impact of global supply chain and logistics issues, tariffs and inflationary trends; the continued expansion of our business outside of the United States; foreign currency risk; our ability to recruit, train and retain highly skilled employees, and the loss of any key personnel; the impact of pandemics or other outbreaks of contagious diseases, and the measures implemented to combat them; the impact of adverse economic conditions; our ability to fully utilize portions of our deferred tax assets; the impact of attention to climate change, conservation measures and other sustainability-related matters; our ability to evaluate or pursue strategic opportunities; our ability to integrate Satcom Direct’s business, and the potential failure to realize or delay in realizing all of the anticipated benefits of the acquisition; the changes in executive management that occurred as part of the Satcom Direct acquisition; our ability to develop and deploy Gogo 5G, Gogo Galileo or other next generation technologies; our ability to maintain our rights to use our licensed 4Mhz of ATG spectrum in the United States and obtain rights to additional spectrum if needed; the impact of service interruptions or delays, cyberattacks, technology failures, equipment damage or system disruptions or failures; the impact of assertions by third parties of infringement, misappropriation or other violations; our ability to innovate and provide products and services; our ability to protect our intellectual property rights; risks associated with the use of artificial intelligence in our products and services; the impact of our use of open-source software; the impact of equipment failure or material defects or errors in our software; our ability to comply with applicable foreign ownership limitations; the impact of government regulation of communication networks, and the internet; the ongoing partial government shutdown; our possession and use of personal information; risks associated with participation in the FCC Reimbursement Program; our ability to comply with anti-bribery, anti-corruption and anti-money laundering laws; the extent of expenses, liabilities or business disruptions resulting from litigation; the impact of global climate change and legal, regulatory or market responses to it; the impact of the distribution of income among various jurisdictions in which we operate as well as changes in tax law or regulation on our U.S. and non-U.S. tax liabilities; the impact of changes in laws and regulations on U.S. government contractors; the impact of our substantial indebtedness; our ability to obtain additional financing to refinance or repay our existing indebtedness the impact of restrictions and limitations in the agreements and instruments governing our debt; the impact of an increase in interest rates; the impact of a substantial portion of our indebtedness being secured by substantially all of our assets; the impact of a substantial change in rating assigned by a rating agency; the volatility of our stock price; our ability to fully utilize our tax losses; the dilutive impact of future stock issuances; the impact of our stockholder concentration; our ability to fulfill the obligations of being  a public company; the impact of an identified material weakness in our internal controls; the impact of certain provisions of our charter, bylaws, and Delaware law; and other factors listed under the caption “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission (“SEC”) on February 27, 2026 and in our subsequent quarterly reports on Form 10-Q as filed with the SEC.

Any one of these factors or a combination of these factors could materially affect our financial condition or future results of operations and could influence whether any forward-looking statements contained in this report ultimately prove to be accurate. Our forward-looking statements are not guarantees of future performance, and you should not place undue reliance on them. All forward-looking statements speak only as of the date made and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0bce0916-2beb-4543-9890-41b6f3fc909c

New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.)

Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives)

BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second major managed Medicare agreement for TONMYA^® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.). Medicare coverage now totals 32 million Medicare lives in the U.S. (58% of approximately 55 million Medicare lives in the U.S.).

Total commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of approximately 314 million total U.S. lives). Previously, Tonix announced commercial payer agreements with two leading group purchasing organizations, and one major managed Medicare agreement. In addition, TONMYA is covered by Medicaid in nearly all states.

“The second major managed Medicare agreement expands patient access to TONMYA, the first fibromyalgia treatment approved in over 15 years,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. “We believe the commercial and managed Medicare coverage agreements reflect TONMYA’s compelling value to patients and payers as a first-in-class, non-opioid analgesic designed for daily bedtime administration and long-term use in adults with fibromyalgia.”

Thomas Englese, MBA, Chief Commercial Officer of Tonix Pharmaceuticals, added, “We remain confident in the trajectory of the TONMYA launch. Our team is focused on executing our strategy across market access, sales, and marketing to improve access for TONMYA and raise awareness for fibromyalgia and TONMYA. This new Medicare coverage agreement is expected to increase patient access to TONMYA. Approximately 50 new sales force representatives have been fully activated in the field, bringing the total sales force to 150 representatives. We are focused on translating the new coverage into more opportunities for fibromyalgia patients to access TONMYA.”

About Fibromyalgia

Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts more than 10 million adults in the U.S., predominantly women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products.

About TONMYA^® (cyclobenzaprine HCl sublingual tablets)

TONMYA (cyclobenzaprine HCl sublingual tablets) was approved on August 15, 2025, by the U.S. Food and Drug Administration (FDA) for the treatment of fibromyalgia in adults. TONMYA is the first new prescription medicine approved for fibromyalgia in more than 15 years. TONMYA provides rapid transmucosal absorption of cyclobenzaprine and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypassing first-pass hepatic metabolism. TONMYA is a multifunctional agent with potent binding and antagonist activities at the 5-HT2A serotonergic, alpha1-adrenergic, H1-histaminergic, and M1-muscarinic receptors. TONMYA was investigated as TNX-102 SL. TNX-102 SL is also being developed to treat acute stress disorder (ASD)/acute stress reaction (ASR), and major depressive disorder (MDD). The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10,357,465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix’s proprietary TONMYA composition. These patents are expected to provide TONMYA with U.S. market exclusivity until 2034.

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs. TONMYA^® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace^® SymTouch^® (sumatriptan injection 3 mg) and Tosymra^® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including Phase 2-ready monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S., and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, TNX-1500 (anti-CD40L mAb) is a Phase 2-ready, third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com.

*Tonix’s product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts

Deborah Elson
Tonix Pharmaceuticals
deborah.elson@tonixpharma.com
investor.relations@tonixpharma.com

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Media Contacts

Andrea Cohen
Sam Brown Inc.
(917) 209-7163
andreacohen@sambrown.com

INDICATION

TONMYA is indicated for the treatment of fibromyalgia in adults.

CONTRAINDICATIONS

TONMYA is contraindicated:

In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected. With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.

During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. In patients with hyperthyroidism.

WARNINGS AND PRECAUTIONS

Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.

Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.

Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.

Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.

CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities. Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS

MAO inhibitors: Life-threatening interactions may occur.

Other serotonergic drugs: Serotonin syndrome has been reported.

CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.

Tramadol: Seizure risk may be enhanced.

Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).

Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of TONMYA have not been established.

Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.

Please see additional safety information in the full Prescribing Information. To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Ad hoc announcement pursuant to Art. 53 LR

MILAN, Italy and MORRISTOWN, N. J., Sept. 22, 2026 (GLOBE NEWSWIRE) — Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the first half of 2026, and provided a corporate update.

Highlights H1 2026:

Evenamide

• ENIGMA-TRS 1: Screening for enrollment completed post-period in September. Target enrollment of at least 600 patients expected around mid-October, Topline 12-week results in Q1 2027
• ENIGMA-TRS 2: Following a constructive Type A meeting with the FDA in July, Newron expects US enrollment to resume in the near future. Ongoing enrollment outside the US
• IP: European Patent Office decision to grant an additional Composition of Matter patent extending protection for evenamide to 2044
• Japan: Partner EA Pharma (Eisai Group) announced initiation of its Phase 3 clinical trial with evenamide in Japan

Corporate

• A financing agreement for proceeds of up to EUR 38 million was signed, strengthening Newron’s financial position and supporting the evenamide Phase 3 program
• Extended maturity of all outstanding European Investment Bank financing tranches to June 2028.
• Post-period, Newron received a further EUR 5.5 million milestone payment from EA Pharma/Eisai
• George Garibaldi and Paolo Zocchi were elected as new, independent non-executive Board members at the AGM

Stefan Weber, CEO of Newron, commented: “During the first half of 2026, we made significant progress advancing evenamide and our pivotal Phase 3 ENIGMA-TRS program. We are very pleased with the continued progress of ENIGMA-TRS 1, with the last patient having completed screening and enrollment expected to reach its target shortly. Following our constructive Type A meeting with the FDA, we also remain confident that enrollment in the US component of ENIGMA-TRS 2 will resume in the near future. Together, these developments bring us closer to potentially delivering a much-needed new treatment option for patients with treatment-resistant schizophrenia. With our strengthened financial position and intellectual property portfolio, Newron is well positioned to advance evenamide towards key ENIGMA-TRS clinical readouts in 2027.”

Evenamide – advancing schizophrenia treatment

Newron continued to make substantial progress with its pivotal ENIGMA-TRS Phase 3 development program during the first half of 2026. The program evaluates evenamide as an add-on therapy in patients with treatment-resistant schizophrenia (TRS), a population that remains underserved by currently available treatments.

ENIGMA-TRS 1 is an international, 52-week, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy, tolerability and safety of the 15mg BID and 30mg BID doses of evenamide compared with placebo. The study is designed to enroll at least 600 patients at centers across Europe, Asia, Latin America and Canada.

Post-period, in September 2026, the last of 996 patients entered screening for enrollment. Newron expects target enrollment of at least 600 patients to be reached around mid-October 2026.

The primary efficacy endpoint is the change from baseline in the Positive and Negative Syndrome Scale (PANSS) score at 12 weeks. Newron expects to announce Topline 12-week results in Q1 2027. The study will continue under double-blind, placebo-controlled conditions through 52 weeks.

ENIGMA-TRS 2 is a 12-week, randomized, double-blind, placebo-controlled Phase 3 study designed to enroll at least 400 patients and evaluate the efficacy, tolerability and safety of the 15mg BID dose of evenamide.

Enrollment started in the US in December 2025, followed by regulatory approvals in study centers in Asia and Latin America. In April 2026, Newron announced a pause in enrollment at US study centers following notification to the FDA of the sudden death of a study participant at a clinical site outside the US, in accordance with standard practice.

Following a constructive Type A meeting with the FDA in July, Newron is implementing changes discussed with the FDA and expects U.S. enrollment to resume following FDA clearance. Study centers outside the US are not affected by the pause.

In January 2026, Newron’s partner EA Pharma (part of the Eisai Group), announced initiation of its Phase 3 clinical trial with evenamide in Japan.

Intellectual property and scientific engagement

In January 2026, the European Patent Office issued a decision to grant Newron an additional Composition of Matter patent providing protection for evenamide through 2044. The patent covers crystalline forms of evenamide, processes for their preparation and their uses, further strengthening the Company’s intellectual property position.

In February, peer-reviewed data was published in Therapeutic Advances in Psychopharmacology. The publication brought together findings from multiple randomized clinical trials and provided further scientific and mechanistic support for evenamide as a novel treatment approach for patients with schizophrenia who have an inadequate response to existing treatments, including those with TRS.

Newron also continued to engage with the scientific and investment communities at key industry and investor conferences during the reporting period.

Xadago®/safinamide – Parkinson’s disease

In partnership with Zambon and Supernus, Newron continues to further develop and market Xadago®/safinamide.

In the US, generic versions of safinamide mesylate are not permitted to launch earlier than December 2027. In the European Union, Newron expects Supplementary Protection Certificates in key markets following completion of ongoing procedures.

Corporate developments

In February, Newron entered into an agreement with existing and new shareholders from Europe and Asia for the subscription of newly issued shares for proceeds of up to EUR 38 million. To date, EUR 20.5 million has been subscribed under the agreement, including a EUR 5.5 million tranche completed post-period in September. The financing further strengthens the Company’s financial position and supports continued execution of the ENIGMA-TRS Phase 3 program.

A further EUR 5.5 million tranche from these investors is expected no later than November 30, 2026, with an additional EUR 12 million expected following disclosure of the ENIGMA-TRS results, conditional upon such results being positive.

In March, Newron announced an agreement with the European Investment Bank extending the maturity date of all outstanding tranches under its 2018 Finance Contract to June 28, 2028.

Post-period, Newron also received a further EUR 5.5 million milestone payment from EA Pharma (Eisai Group), reflecting continued progress in the development of evenamide.

At the Annual General Meeting in April, George Garibaldi and Paolo Zocchi were elected as new independent non-executive Board members, succeeding Patrick Langlois and Luca Benatti.

Financial key takeaways H1 2026

• For the first six months of 2026, Newron reported revenues of EUR 3.2 million, compared to EUR 11.9 million in the same period of 2025. H1 2025 revenues reflect the achievement of the first milestone under the license agreement with EA Pharma (Eisai Group) and the upfront payment received from Myung In Pharm.
• Newron’s R&D expenses increased to EUR 14.6 million in H1 2026, up from EUR 6.1 million in H1 2025.
• This resulted in a net loss of EUR 16.4 million, compared to EUR 0.1 million in the same period in 2025.
• Operating activities absorbed EUR 10.8 million while as of June 2025 they generated EUR 33.4 million of cash.
• Cash and Other current financial assets as at June 30, 2026, were at EUR 32.9 million, compared to EUR 28.9 million as at December 31, 2025. Post period, in September, the cash balance was positively impacted by the milestone payment and the call for the second tranche of financing, by a total of about EUR 11.0 million.

Financial Summary (IFRS) H1 2026 and H1 2025

In thousand EUR (except per share information), unaudited

	H1 2026		H1 2025
Licence income from contracts with customers	125		7,772
Royalties from contracts with customers	3,064		3,780
Other income from contracts with customers	0		346
Revenues	3,189		11,898
Research and development expenses	(14,552	)	(6,081	)
Operating Result	(16,600	)	1,345
Financial result	235		(1,402	)
Net result	(16,372	)	(73	)
Result per share	(0.798	)	(0.004	)
	June 30, 2026		Dec. 31, 2025
Cash and cash equivalents, other current financial assets	32,890		28,876
Total assets	40,291		40,055

Newron’s Half-Year 2026 is available for download on the Company’s website at:
www.newron.com/investors/reports-and-presentation/year/2026

Outlook

Newron is well positioned to continue advancing the clinical development of evenamide through the remainder of 2026 and into 2027.

The Company’s key priority remains the successful execution of the pivotal ENIGMA-TRS Phase 3 program. With ENIGMA-TRS 1 approaching target enrollment and US enrollment in ENIGMA-TRS 2 expected to resume in the near future, Newron remains focused on achieving important clinical milestones and expects topline results from both studies in 2027.

Newron also continues to explore development and commercial opportunities for evenamide and to strengthen its intellectual property position.

The Company’s total available cash resources are expected to fund planned development programs and operations throughout most of 2027, including beyond the expected disclosure of the 12-week results from the ENIGMA-TRS program.

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase 3 development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com and connect with us on LinkedIn.

For more information:

Newron
Stefan Weber – CEO; pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com   

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
John Fraunces, LifeSci Advisors, +1 917 355 2395, jfraunces@lifesciadvisors.com

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

MONTREAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; NASDAQ: AYA) (“Aya” or the “Company”) is pleased to report new high-grade drill exploration results at the Boumadine Project (“Boumadine” or the “Project”) from its ongoing infill drill program in the Kingdom of Morocco. These results confirm strong high-grade continuity along the Boumadine Main Trend and support the potential for continued resource growth.

Highlights¹

Boumadine Main Trend (5.4km)

• Multiple additional high-grade intercepts:
  • BOU-DD26-848 intercepted 392 grams per tonne (“g/t”) silver equivalent (“AgEq”) over 24.3 metres (“m”) (0.61 g/t gold (“Au”), 239 g/t silver (“Ag”), 2.6% zinc (“Zn”), and 1.9% lead (“Pb”), including 776 g/t AgEq over 10.0m (1.08 g/t Au, 488 g/t Ag, 5.2% Zn, and 3.9% Pb).
  • BOU-DD26-883 intercepted 593 g/t AgEq over 15.2m (1.05 g/t Au, 319 g/t Ag, 5.3% Zn and 3.5% Pb), including 1,038 g/t AgEq over 4.2m (1.81 g/t Au, 586g/t Ag, 8.1% Zn and 6.2% Pb).
  • BOU-DD26-0950 intercepted 299 g/t AgEq over 15.1m (1.70 g/t Au, 98 g/t Ag, 1.7% Zn and 0.6% Pb).
  • BOU-DD26-861 intercepted 1,030 g/t AgEq over 4.1m (1.06 g/t Au, 794 g/t Ag, 4.2% Zn, and 1.8% Pb) including 2,827 g/t AgEq over 1.0m (1.90 g/t Au, 2,477g/t Ag, 3.4% Zn and 3.2% Pb).
  • BOU-DD26-834 intercepted 696 g/t AgEq over 5.7m (2.70 g/t Au, 342 g/t Ag, 3.8% Zn and 1.3% Pb) and 277 g/t AgEq over 6.9m (0.56 g/t Au, 151g/t Ag, 2.1% Zn and 1.4% Pb).
• Exploration Update:
  • 145,719m drilled at Boumadine year-to-date.
  • 38.6% of the 360,000m infill program, to be carried out over 2026 and 2027, has been completed.

“Today’s high-grade results continue to demonstrate the continuity, width and potential at Boumadine,” said Benoit La Salle, President & CEO. “With over 145,000 metres drilled year-to-date and 14 drills currently turning, we are aggressively advancing the 2026–2027 infill and expansion program ahead of the updated Feasibility Study expected next year.”

Table 1 – Significant Intercepts from Boumadine Drill Exploration Program (Core Lengths)

DDH No.	From	To	Au	Ag	Length*	Cu	Pb	Zn	Mo	Ag Eq2
	(m)	(m)	(g/t)	(g/t)	(m)	(%)	(%)	(%)	(g/t)	(g/t)
BOU-DD26-807	458.8	467.7	0.65	92	8.9	0.0	1.4	2.6	92	231
BOU-DD26-814	213.5	226.6	0.63	145	13.1	0.0	1.4	1.7	61	267
BOU-DD26-817	237.2	247.0	0.73	168	9.8	0.0	0.9	1.2	103	278
Including	238.2	241.5	1.66	408	3.3	0.0	2.5	2.7	196	664
BOU-DD26-823	79.5	84.7	0.39	407	5.2	0.0	4.7	3.1	14	596
Including	79.5	82.7	0.44	595	3.2	0.0	5.7	4.1	16	829
BOU-DD26-834	367.6	373.3	2.70	342	5.7	0.1	1.3	3.8	292	696
BOU-DD26-834	375.3	382.2	0.56	151	6.9	0.0	1.4	2.1	190	277
BOU-DD26-838	230.3	235.3	1.45	356	5.0	0.0	2.9	3.3	694	622
Including	231.3	233.3	3.00	835	2.0	0.1	6.8	7.4	1,558	1,413
BOU-DD26-839	309.0	314.6	1.27	138	5.6	0.0	1.5	2.4	46	333
BOU-DD26-847	193.4	201.6	0.47	246	8.2	0.0	3.6	2.3	352	410
Including	194.3	195.6	2.15	1,155	1.3	0.1	16.4	5.7	680	1,789
BOU-DD26-847	204.2	209.0	0.61	242	4.8	0.0	3.1	4.5	292	454
Including	205.8	208.0	1.08	438	2.2	0.1	6.1	8.2	389	827
BOU-DD26-848	259.7	284.0	0.61	239	24.3	0.1	1.9	2.6	296	392
Including	265.6	275.6	1.08	488	10.0	0.1	3.9	5.2	170	776
BOU-DD26-861	213.8	217.9	1.06	794	4.1	0.1	1.8	4.2	605	1,030
Including	216.0	217.0	1.90	2,477	1.0	0.4	3.2	3.4	997	2,827
BOU-DD26-883	249.0	264.2	1.05	319	15.2	0.0	3.5	5.3	153	593
Including	249.8	254.0	1.81	586	4.2	0.1	6.2	8.1	128	1,038
BOU-DD26-900	253.0	267.0	1.00	85	14.0	0.1	0.8	3.2	135	268
BOU-DD26-901	446.8	467.5	0.55	54	20.7	0.0	0.7	1.9	32	160
BOU-DD26-920	215.5	223.5	0.51	204	8.0	0.0	2.9	3.3	199	378
BOU-DD26-0926	124.1	134.0	0.45	173	9.9	0.0	0.7	1.7	16	265
Including	128.0	131.0	1.02	423	3.0	0.1	1.0	3.3	13	608
BOU-DD26-0929	41.7	53.5	1.76	50	11.8	0.1	0.5	0.5	3	234
Including	47.9	51.7	3.89	116	3.8	0.2	0.5	0.8	4	506
BOU-DD26-0950	19.0	34.1	1.70	98	15.1	0.0	0.6	1.7	64	299
BOU-DD26-0961	278.3	294.4	1.51	14	16.1	0.1	0.0	0.0	8	156
BOU-DD26-0969	207.4	218.0	2.37	29	10.6	0.1	0.1	0.3	8	260
BOU-DD26-0973	62.0	70.6	0.74	47	8.6	0.1	0.8	7.3	20	280
Including	65.9	69.0	1.14	88	3.1	0.1	1.8	17.3	25	585
BOU-DD26-0976	152.0	154.0	0.03	1,867	2.0	0.0	0.6	0.9	8	1,902
BOU-DD26-0979	221.0	226.5	3.55	64	5.5	0.1	0.3	0.1	21	397
BOU-DD26-1005	16.2	28.2	1.36	47	12.0	0.0	0.2	0.0	67	175
BOU-DD26-1018	136.9	147.0	2.26	20	10.1	0.0	0.7	0.5	13	248

1. Ag equivalent is based on a silver price of US$30/oz with a process recovery of 96%, a gold price of US$2,800/oz with a process recovery of 96%, a zinc price of US$1.20/lb with a process recovery of 75%, a lead price of US$1.00/lb with a process recovery of 82%, and a copper price of US$4.60/lb with a process recovery of 75% resulting in the following ratios: 1g/t Au: 89.7g/t Ag; 1% Cu: 78.6 g/t Ag; 1% Pb: 18.7 g/t Ag; and 1% Zn: 20.4 g/t Ag.
2. True width remains undetermined at this stage; all values are uncut.

Figure 1: Boumadine Mining Licence Surface Plan with Magnetic Data (Residual Total Field) and 2026 Drill Holes

2026 Exploration Results

This year, 406 diamond drill holes (“DDH”), totaling 145,719m have been completed at Boumadine (Figure 1 and Appendix 2). Drilling was done on strike along the Main Trend, Tizi and Imariren. All results have been received for drill holes up to BOU-DD26-1028 (Table 1, Figure 2, Figure 3 and Appendix 1).

Today’s results, including BOU-DD26-848 and BOU-DD26-883, confirm the high-grade nature and continuity of the Boumadine Main Trend, which remains open in all directions.

Mineralization within the Boumadine Main Trend measures up to 4m wide (locally reaching over a 10m width) and is N340-oriented massive sulphide lenses/veins sharply dipping eastward (> 70°). The massive sulphide veins (>80%) are mainly composed of pyrite, with variable proportions of sphalerite, galena, and chalcopyrite. Tizi and Imariren share the same characteristics except for their N000 orientation.

Figure 2 – Surface Plan of Boumadine South Zone with New DDH Results

Figure 3 – Surface Plan of Boumadine North Zone with New DDH Results

Next Steps

Infill drilling, following the latest positive preliminary economic assessment (“PEA”), will be ongoing for the next 15 months with a drill program of approximately 360,000m planned.

Significant potential exists to expand the Boumadine Main Trend (currently 5.4 km), the Tizi Zone (2.0 km) and the Imariren Zone (1.2 km), with all three trends open in all directions. Follow-up drilling is also planned on the 8 km Asirem trend for later this year.

Most drilling will continue to focus on the Main Trend, Imariren and Tizi to extend known mineralization along strike and at depth, while infilling key areas to advance the Project toward a Feasibility Study (“FS”). The balance of the 2026 program (~20,000m) will target Asirem follow-up and greenfield exploration, testing geological hypotheses and targets generated over the past four years. Ongoing geological work will guide additional development priorities.

Technical Information

Aya has implemented a quality control program to comply with best practices in sampling and analysis of drill core and RC chips. For core drilling, all individual samples represent approximately one metre in length of core, which is halved. Half of the core is kept on site for reference, and its counterpart is sent for preparation and assaying to African Laboratory for Mining and Environment (“Afrilab”) in Marrakech, Morocco. For drilling using RC, all individual samples represent 1.0m in length and a representative portion is kept for every metre in some chip trays stored on site. A split samples representing 1/16th, ranging from 2 to 4 kilogram is sent for preparation and assaying to African Laboratory for Mining and Environment (“Afrilab”) in Marrakech, Morocco.

All samples are analyzed for silver, copper, iron, lead, zinc, tin, and molybdenum using Aqua regia and finished by atomic absorption spectroscopy (“AAS”). Samples grading above 200 g/t Ag are reanalyzed using fire assaying. Gold is assayed by fire assaying. Standards of different grades and blanks were inserted every 20 samples in addition to the standards, blanks and pulp duplicate inserted by Afrilab.

Qualified Person

The scientific and technical information contained in this press release have been reviewed by David Lalonde, B. Sc, P. Geo, Executive Vice-President Exploration, who is a “Qualified Person” as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”), for accuracy and compliance with NI 43-101.

About Aya Gold & Silver Inc.

Aya Gold & Silver is a Canadian precious metals mining company anchored in Morocco and active across the full mining value chain. The Company has established an exploration track record through a systematic, technology-led, data-driven approach and is focused on expanding its resource base and land package along the Anti-Atlas fault — one of Africa’s most geologically rich, underexplored and mining-friendly regions.

Aya operates Zgounder, a rare, silver-only mine, producing silver doré from its new processing facility. Aya’s growth pipeline includes the Boumadine polymetallic project, where feasibility study work is underway, and which hosts a sizable mineralized footprint, and potential for further discovery.

Led by a proven team of mining professionals, Aya is guided by a vision of responsible mining and is committed to delivering sustainable value for shareholders, employees and host communities.

For additional information, please visit Aya’s website at www.ayagoldsilver.com.

Or contact

Benoit La Salle, FCPA, MBA President & CEO Benoit.lasalle@ayagoldsilver.com

Alex Ball EVP, Capital Markets alex.ball@ayagoldsilver.com

Forward-Looking Statements

This press release contains “forward-looking statements” or “forward-looking information” within the meaning of applicable securities laws and other statements that are not historical facts. Forward-looking statements are included to provide information about management’s current expectations, estimates and projections regarding Aya’s future growth and business prospects (including the timing and development of deposits and the success of exploration activities) and other opportunities as of the date of this press release.

All statements, other than statements of historical fact included in this press release, regarding the Company’s strategy, future operations, technical assessments, prospects, plans and objectives of management are forward-looking statements that involve risks and uncertainties. Wherever possible, words such as “aim”, “anticipate”, “assume”, “believe”, “estimate”, “expect”, “goal”, “guidance”, “intend”, “objective”, “plan”, “potential”, “strategy”, “target”, and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, have been used to identify such forward-looking information. Forward-looking statements in this press release include, but are not limited to, statements with respect to: the potential for continued mineral resource growth and further expansion of mineralization along the Boumadine Main Trend in all directions; the Boumadine 2026 and 2027 exploration program; the expected completion date and content of the Boumadine feasibility study; the next steps with respect to the development and exploration of the Boumadine project, including infill drilling over the next 15 months, a drill program of approximately 360,000 m, follow-up drilling on the 8 km Asirem trend, testing and geological work.

Forward-looking information is based upon certain assumptions and other important factors that, if untrue, could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such information or statements. There can be no assurance that such information or statements will prove to be accurate. Key assumptions upon which the Company’s forward-looking information is based include without limitation, assumptions regarding development and exploration activities; the Company’s ability to execute its business plans and objectives; the ability to commence and successfully execute planned drilling and exploration activities; the accuracy of the Company’s geological interpretations and the continuity of mineralization in areas targeted for exploration; the continued validity and good standing of the mining titles necessary to conduct the planned exploration activities; the timely receipt of necessary approvals or permits; the ability to obtain timely financing on reasonable terms when required; future social, economic and political conditions remaining consistent with those currently prevailing; the availability of qualified contractors, consultants, suppliers, equipment, materials and labour on commercially reasonable terms; the cooperation of government authorities, municipalities and other stakeholders; future drilling results being generally consistent with the Company’s expectations and current geological interpretations; the ability to complete planned infill and exploration drilling substantially in accordance with the anticipated scope and timelines; the availability and reliability of the technical, geological, metallurgical, engineering, environmental and economic information required to complete the feasibility study within the scope currently contemplated; and the successful completion of the required studies and the feasibility study within the anticipated timeframe.

Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Forward-looking statements are also subject to risks and uncertainties facing the Company’s business, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects. Some of the risks the Company faces and the uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements include, among others: Aya’s ability to execute on its plans relating to the Boumadine Project, including the timing thereof; the speculative nature of mineral exploration and development; the inherent risks involved in the exploration and development of mineral properties; the risk that exploration, drilling, testing and geological work may not result in the discovery of additional mineralization or the expansion or conversion of mineral resources as anticipated; the risk that future drilling results may not be consistent with the Company’s expectations or current geological interpretations; the risk that the continuity, grade and extent of mineralization may differ from current interpretations and estimates; risks and uncertainties relating to the timing, scope, completion and results of the Company’s planned exploration and drilling programs; risks and uncertainties relating to the timing, scope, assumptions, conclusions and results of the feasibility study; the risk that geological, metallurgical, engineering, environmental and other technical information required to complete the feasibility study may be unavailable, incomplete or unreliable; risks and hazards associated with the business of mineral exploration, development and mining, including environmental hazards, industrial accidents and unusual or unexpected geological or structural formations; risks related to Aya’s operations in Morocco; Aya’s ability to obtain and renew necessary permits and licences; restrictions on mining and changes in laws and regulations governing exploration and development activities in the jurisdictions in which Aya operates; inadequate or unreliable infrastructure; Aya’s ability to attract and retain qualified employees and contractors and the availability of qualified contractors, consultants, suppliers, equipment and materials; Aya’s ability to obtain financing when required on acceptable terms; unforeseen expenses and cost increases; disruptions to Aya’s business operations; third-party risks; occupational health and safety risks; climate change and weather disruptions; general economic conditions; competition risk; force majeure; and other risks described in the Company’s documents filed with Canadian and U.S. securities regulatory authorities.

In addition, readers are directed to carefully review the detailed risk discussion in the Company’s Annual Information Form and Management’s Discussion & Analysis for the year ended December 31, 2025, filed on SEDAR+ and on EDGAR, which discussions are incorporated by reference in this press release, for a fuller understanding of the risks and uncertainties that affect the Company’s business and operations.

Although the Company believes its expectations are based upon reasonable assumptions and has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. As such, these risks are not exhaustive; however, they should be considered carefully. If any of these risks or uncertainties materialize, actual results may vary materially from those anticipated in the forward-looking statements found herein. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on forward-looking statements.

Forward-looking statements contained herein are presented for the purpose of assisting investors in understanding the Company’s business plans, financial performance and condition and may not be appropriate for other purposes.

The forward-looking statements contained herein are made only as of the date hereof. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law. The Company qualifies all of its forward-looking statements by these cautionary statements.

The Company may make decisions to advance the development of its mineral projects prior to the completion of a feasibility study establishing mineral reserves that demonstrate economic and technical viability. The decision to proceed with development in the absence of such a feasibility study involves materially greater technical and economic risks, including increased uncertainty as to mineral recovery, capital and operating costs, production rates, mine design and overall economic viability. There can be no assurance that any project advanced on this basis will ultimately be technically or economically viable or achieve the anticipated results.

Appendix 1 – Full Drill Results from Boumadine (core lengths)

DDH No.	From	To	Au	Ag	Length*	Cu	Pb	Zn	Mo	Ag Eq**
	(m)	(m)	(g/t)	(g/t)	(m)	(%)	(%)	(%)	(g/t)	(g/t)
BOU-DD26-766	193.4	198.2	0.89	167	4.8	0.0	0.8	2.0	7	304
BOU-DD26-766	204.1	207.0	0.37	89	2.9	0.0	0.4	0.5	12	139
BOU-DD26-801	322.7	324.1	0.30	32	1.4	0.0	0.8	1.2	29	103
BOU-DD26-801	437.0	438.0	0.49	41	1.0	0.0	0.4	0.5	843	116
BOU-DD26-801	447.6	448.4	0.30	44	0.8	0.0	1.2	1.8	68	133
BOU-DD26-802	206.7	207.5	0.19	51	0.8	0.1	0.6	0.9	5	103
BOU-DD26-803	273.5	274.8	0.81	16	1.3	0.0	0.2	0.3	4	100
BOU-DD26-803	354.0	355.5	0.87	66	1.5	0.1	0.2	0.7	10	167
BOU-DD26-804	120.0	121.0	0.49	27	1.0	0.0	0.1	0.3	8	79
BOU-DD26-804	198.0	200.1	1.45	95	2.1	0.2	3.7	5.7	1	427
BOU-DD26-804	206.4	207.2	1.13	18	0.8	0.0	0.6	3.0	3	195
BOU-DD26-804	404.0	404.5	0.96	34	0.5	0.0	0.2	0.3	1	131
BOU-DD26-805	265.9	266.8	0.49	26	0.9	0.0	0.1	0.2	5	75
BOU-DD26-805	267.7	274.5	0.47	117	6.8	0.0	1.0	1.7	40	214
Including	271.2	272.6	1.07	397	1.4	0.0	3.1	5.2	65	659
BOU-DD26-805	307.2	308.2	1.03	5	1.0	0.0	0.0	0.1	5	100
BOU-DD26-805	338.2	339.2	0.88	156	1.0	0.0	2.0	6.4	883	420
BOU-DD26-805	348.7	352.6	0.72	66	3.9	0.0	0.9	0.8	10	164
BOU-DD26-805	358.6	360.3	0.52	243	1.7	0.0	2.6	3.7	62	416
BOU-DD26-805	371.5	372.4	0.28	53	0.9	0.0	1.2	4.0	77	183
BOU-DD26-806	27.4	27.9	1.71	16	0.5	0.1	0.1	0.1	8	184
BOU-DD26-806	32.2	33.1	0.21	46	0.9	0.2	0.4	0.3	20	91
BOU-DD26-806	106.3	107.0	0.38	32	0.7	0.1	0.5	0.7	6	94
BOU-DD26-806	258.8	259.3	0.47	39	0.5	0.0	0.2	1.1	12	111
BOU-DD26-806	282.0	283.2	2.62	29	1.2	0.0	0.0	0.0	7	268
BOU-DD26-807	267.0	268.0	0.63	6	1.0	0.0	0.0	0.0	12	64
BOU-DD26-807	322.6	323.6	1.41	4	1.0	0.0	0.0	0.0	9	131
BOU-DD26-807	346.7	347.2	0.39	56	0.5	0.0	0.3	1.4	31	126
BOU-DD26-807	431.6	432.6	0.59	10	1.0	0.0	0.1	0.2	4	69
BOU-DD26-807	446.8	448.3	1.31	102	1.5	0.0	0.6	1.5	63	263
BOU-DD26-807	449.2	450.1	0.56	9	0.9	0.0	0.0	0.0	6	61
BOU-DD26-807	453.0	454.8	0.82	66	1.8	0.0	0.6	2.2	38	198
BOU-DD26-807	458.8	467.7	0.65	92	8.9	0.0	1.4	2.6	92	231
Including	466.1	467.7	1.66	245	1.6	0.0	3.5	6.4	272	596
BOU-DD26-807	470.4	471.3	0.56	41	0.9	0.0	0.5	2.0	176	144
BOU-DD26-807	487.9	488.5	0.62	26	0.6	0.0	0.1	0.4	6	91
BOU-DD26-808	154.0	155.0	0.76	21	1.0	0.0	0.2	0.4	2	101
BOU-DD26-808	158.0	161.0	0.27	36	3.0	0.0	0.8	1.1	6	97
BOU-DD26-808	185.6	188.0	0.43	294	2.4	0.0	0.5	1.2	7	368
BOU-DD26-808	224.0	225.0	0.29	149	1.0	0.3	9.0	5.8	4	485
BOU-DD26-808	229.0	230.0	0.74	26	1.0	0.0	0.1	0.3	28	102
BOU-DD26-808	256.0	259.0	0.64	10	3.0	0.0	0.2	0.3	6	78
BOU-DD26-808	262.0	263.0	0.53	46	1.0	0.0	0.1	0.1	7	97
BOU-DD26-808	315.4	317.0	0.67	7	1.6	0.0	0.1	0.1	5	72
BOU-DD26-808	366.2	367.6	0.71	15	1.4	0.0	0.1	0.5	10	91
BOU-DD26-808	395.1	395.6	1.69	23	0.5	0.1	0.5	0.3	13	198
BOU-DD26-808	396.5	397.1	0.60	16	0.6	0.1	0.4	0.2	5	86
BOU-DD26-808	413.0	413.7	0.41	20	0.7	0.1	0.5	1.5	5	101
BOU-DD26-809	99.5	102.1	3.25	32	2.6	0.2	0.1	0.2	9	345
BOU-DD26-809	165.8	166.4	0.88	39	0.6	0.1	2.5	1.8	2	208
BOU-DD26-809	283.0	284.0	0.80	27	1.0	0.0	0.1	0.1	3	104
BOU-DD26-810	109.1	111.2	0.35	36	2.1	0.0	0.1	0.5	17	80
BOU-DD26-811	0.0	252.0								NSR
BOU-DD26-812	128.0	129.0	0.10	50	1.0	0.1	0.2	1.3	8	97
BOU-DD26-812	135.9	138.5	0.56	20	2.6	0.0	0.6	0.2	6	87
BOU-DD26-812	295.0	296.0	0.54	4	1.0	0.0	0.1	0.1	12	56
BOU-DD26-813	108.0	109.0	0.83	0	1.0	0.0	0.0	0.0	3	75
BOU-DD26-814	213.5	226.6	0.63	145	13.1	0.0	1.4	1.7	61	267
Including	214.4	217.4	1.47	360	3.0	0.0	0.8	2.8	70	566
BOU-DD26-814	230.4	231.4	0.11	40	1.0	0.0	0.4	1.3	13	84
BOU-DD26-814	232.4	233.4	0.34	115	1.0	0.0	1.2	2.2	12	213
BOU-DD26-814	259.3	260.3	1.00	18	1.0	0.0	0.1	0.0	10	111
BOU-DD26-814	264.3	264.8	1.10	37	0.5	0.0	0.1	0.1	17	139
BOU-DD26-815	215.0	215.8	0.60	49	0.8	0.0	0.2	1.1	32	131
BOU-DD26-815	229.1	236.8	0.90	37	7.7	0.0	0.2	2.4	18	174
Including	233.0	236.8	1.38	58	3.8	0.1	0.2	4.5	19	282
BOU-DD26-815	258.0	259.0	1.06	981	1.0	1.0	0.2	0.7	51	1,174
BOU-DD26-815	274.0	275.0	0.78	2	1.0	0.0	0.1	0.1	9	76
BOU-DD26-815	397.3	397.9	0.13	49	0.6	0.0	0.4	0.5	11	79
BOU-DD26-816	156.5	157.0	0.58	33	0.5	0.0	0.6	0.7	6	112
BOU-DD26-817	165.3	165.9	0.40	47	0.6	0.0	0.3	0.1	7	93
BOU-DD26-817	180.8	181.6	0.89	30	0.8	0.0	0.1	0.0	16	113
BOU-DD26-817	182.2	182.8	0.42	22	0.6	0.0	0.4	0.1	17	72
BOU-DD26-817	237.2	247.0	0.73	168	9.8	0.0	0.9	1.2	103	278
Including	238.2	241.5	1.66	408	3.3	0.0	2.5	2.7	196	664
BOU-DD26-817	251.0	253.0	0.10	54	2.0	0.0	0.0	0.1	17	65
BOU-DD26-817	255.7	256.3	0.64	111	0.6	0.0	0.0	0.0	11	170
BOU-DD26-818	0.0	270.0	0.00	0	270.0	0.0	0.0	0.0	0	0
BOU-DD26-819	256.1	256.6	0.70	20	0.5	0.0	0.8	1.6	5	131
BOU-DD26-820	7.4	9.0	0.60	24	1.6	0.1	1.7	0.1	20	115
BOU-DD26-821	141.9	148.5	0.43	63	6.6	0.2	1.5	2.1	6	192
Including	141.9	145.4	0.47	93	3.5	0.3	2.4	2.7	10	260
BOU-DD26-821	239.0	240.0	0.09	51	1.0	0.0	5.1	1.8	1	195
BOU-DD26-821	314.0	314.8	0.67	9	0.8	0.0	0.2	0.7	2	90
BOU-DD26-822	224.0	224.7	0.27	54	0.7	0.0	0.4	0.5	390	103
BOU-DD26-822	303.5	304.0	0.96	87	0.5	0.0	1.0	4.4	20	283
BOU-DD26-823	79.5	84.7	0.39	407	5.2	0.0	4.7	3.1	14	596
Including	79.5	82.7	0.44	595	3.2	0.0	5.7	4.1	16	829
BOU-DD26-823	95.9	97.5	0.71	343	1.6	0.0	1.9	7.1	10	589
BOU-DD26-823	110.0	111.0	2.49	7	1.0	0.0	0.0	0.0	0	231
BOU-DD26-823	114.0	115.0	1.24	14	1.0	0.0	0.3	1.0	1	152
BOU-DD26-824	34.7	35.4	0.14	41	0.7	0.1	1.9	3.1	6	158
BOU-DD26-825	236.6	237.3	1.61	79	0.7	0.0	2.0	6.2	1,484	414
BOU-DD26-825	255.0	256.0	0.20	54	1.0	0.0	0.1	1.2	28	98
BOU-DD26-825	262.0	263.0	0.09	67	1.0	0.0	0.1	0.0	88	80
BOU-DD26-825	268.9	269.9	0.45	38	1.0	0.0	0.3	2.1	40	129
BOU-DD26-825	374.2	376.1	0.57	38	1.9	0.0	0.1	0.3	20	100
BOU-DD26-825	414.8	415.5	0.49	39	0.7	0.1	0.1	0.0	80	91
BOU-DD26-825	462.8	463.5	1.31	28	0.7	0.0	0.1	1.0	35	170
BOU-DD26-826	161.5	162.0	0.54	43	0.5	0.1	0.0	0.0	36	96
BOU-DD26-826	451.0	451.8	0.77	15	0.8	0.0	0.0	0.0	22	86
BOU-DD26-826	493.0	494.0	1.14	19	1.0	0.0	0.1	0.1	37	127
BOU-DD26-826	498.3	501.0	0.68	41	2.7	0.1	0.1	0.4	138	118
BOU-DD26-826	519.6	521.9	0.73	35	2.3	0.1	0.1	0.4	118	123
BOU-DD26-827	0.0	282.0								NSR
BOU-DD26-828	265.5	266.1	0.69	19	0.6	0.0	0.3	1.0	10	109
BOU-DD26-828	286.2	288.0	2.37	91	1.8	0.1	2.4	3.4	4	425
BOU-DD26-828	341.6	343.3	2.71	84	1.7	0.1	3.2	6.6	5	529
BOU-DD26-829	159.0	160.7	0.03	64	1.7	0.0	0.0	0.0	3	68
BOU-DD26-829	161.6	162.5	0.03	60	0.9	0.0	0.0	0.0	2	63
BOU-DD26-830	325.4	326.0	0.47	32	0.6	0.0	0.3	1.6	18	113
BOU-DD26-830	348.0	349.0	0.80	3	1.0	0.0	0.1	0.2	15	82
BOU-DD26-830	475.0	476.0	0.26	55	1.0	0.0	0.2	0.0	1	83
BOU-DD26-830	509.1	511.5	0.54	23	2.4	0.1	0.4	0.6	10	95
BOU-DD26-830	540.1	541.0	0.59	25	0.9	0.0	2.1	2.2	14	164
BOU-DD26-830	549.8	551.3	1.60	48	1.5	0.2	0.8	0.6	21	235
BOU-DD26-831	318.8	319.7	13.22	265	0.9	0.7	2.6	3.3	5	1,617
BOU-DD26-831	322.7	323.7	0.68	43	1.0	0.1	1.7	5.7	7	257
BOU-DD26-831	352.5	354.8	2.30	109	2.3	0.1	2.4	4.2	5	456
BOU-DD26-831	356.0	356.8	0.05	49	0.8	0.0	1.7	5.2	4	196
BOU-DD26-832	117.6	118.1	0.84	20	0.5	0.0	0.1	0.5	6	110
BOU-DD26-833	60.4	61.0	0.63	23	0.6	0.0	0.1	0.2	10	87
BOU-DD26-833	61.5	63.1	0.31	46	1.6	0.0	0.6	1.6	11	118
BOU-DD26-833	84.0	89.6	0.37	62	5.6	0.0	1.1	2.2	22	164
BOU-DD26-834	286.7	288.8	0.62	41	2.1	0.0	0.2	2.3	110	151
BOU-DD26-834	300.2	300.8	0.69	10	0.6	0.0	0.0	0.0	42	74
BOU-DD26-834	367.6	373.3	2.70	342	5.7	0.1	1.3	3.8	292	696
BOU-DD26-834	375.3	382.2	0.56	151	6.9	0.0	1.4	2.1	190	277
BOU-DD26-834	416.0	421.5	0.81	29	5.5	0.0	0.2	0.7	182	122
BOU-DD26-835	40.9	41.9	0.59	33	1.0	0.4	1.7	3.7	72	224
BOU-DD26-835	174.3	175.6	0.37	44	1.3	0.1	0.1	0.5	6	95
BOU-DD26-835	360.6	362.8	4.77	101	2.2	0.2	0.2	0.7	6	560
BOU-DD26-836	139.1	139.7	1.18	25	0.6	0.1	0.2	1.1	1	164
BOU-DD26-836	277.5	278.4	0.52	14	0.9	0.0	0.5	1.0	5	90
BOU-DD26-837	305.8	307.4	0.56	14	1.6	0.1	0.4	0.3	3	82
BOU-DD26-838	211.7	212.6	0.40	66	0.9	0.0	0.6	0.8	13	130
BOU-DD26-838	230.3	235.3	1.45	356	5.0	0.0	2.9	3.3	694	622
Including	231.3	233.3	3.00	835	2.0	0.1	6.8	7.4	1,558	1,413
BOU-DD26-838	243.1	244.0	0.43	40	0.9	0.1	0.2	2.5	88	138
BOU-DD26-838	245.0	246.0	0.17	53	1.0	0.0	2.8	2.1	41	165
BOU-DD26-838	251.8	253.1	0.15	60	1.3	0.0	3.7	3.3	19	211
BOU-DD26-838	307.0	308.0	0.45	25	1.0	0.0	0.5	1.6	9	107
BOU-DD26-838	349.0	349.7	1.18	65	0.7	0.0	1.9	3.7	8	285
BOU-DD26-838	353.7	354.2	0.39	58	0.5	0.0	2.7	4.4	10	235
BOU-DD26-839	166.5	167.0	0.64	26	0.5	0.0	0.1	0.3	9	92
BOU-DD26-839	309.0	314.6	1.27	138	5.6	0.0	1.5	2.4	46	333
BOU-DD26-839	318.3	319.3	0.38	20	1.0	0.0	0.5	0.0	6	66
BOU-DD26-839	350.0	351.0	0.36	18	1.0	0.0	0.0	0.0	34	52
BOU-DD26-839	385.6	386.2	2.86	139	0.6	0.0	1.6	4.9	2,507	572
BOU-DD26-839	406.6	407.2	0.75	66	0.6	0.0	0.2	0.1	96	140
BOU-DD26-840	81.6	82.3	0.55	40	0.7	0.2	0.1	0.5	6	114
BOU-DD26-840	83.6	84.2	0.03	101	0.6	0.2	0.1	6.6	7	251
BOU-DD26-840	210.7	211.2	0.67	15	0.5	0.0	0.4	0.3	8	90
BOU-DD26-841	26.3	26.8	1.15	47	0.5	0.1	1.1	2.4	0	225
BOU-DD26-841	137.8	138.4	0.93	36	0.6	0.1	1.0	3.1	7	211
BOU-DD26-841	205.7	206.7	0.17	60	1.0	0.3	0.1	0.1	6	99
BOU-DD26-841	313.2	314.2	0.03	128	1.0	0.0	0.1	0.1	1	135
BOU-DD26-842	0.0	207.0								NSR
BOU-DD26-843	0.0	270.0								NSR
BOU-DD26-844	103.2	104.1	0.15	54	0.9	0.0	0.5	1.3	12	105
BOU-DD26-844	150.0	152.0	0.90	3	2.0	0.0	0.1	0.2	2	89
BOU-DD26-844	171.0	172.0	0.89	16	1.0	0.0	0.0	0.0	9	97
BOU-DD26-844	175.3	177.0	1.04	47	1.7	0.0	0.8	5.3	13	266
BOU-DD26-845	100.8	101.7	0.18	48	0.9	0.0	0.8	1.1	7	102
BOU-DD26-845	106.9	110.1	0.62	66	3.2	0.0	2.1	2.8	15	219
BOU-DD26-845	409.7	410.7	1.27	56	1.0	0.1	1.1	2.1	9	244
BOU-DD26-845	421.2	421.7	0.23	37	0.5	0.4	0.1	0.6	6	100
BOU-DD26-846	72.0	72.6	0.41	41	0.6	0.0	0.2	0.9	5	103
BOU-DD26-846	171.5	172.5	1.96	15	1.0	0.0	0.0	0.1	5	195
BOU-DD26-846	175.2	176.5	0.37	32	1.3	0.1	0.0	0.3	4	84
BOU-DD26-846	203.5	204.4	0.13	203	0.9	0.5	0.5	0.4	5	268
BOU-DD26-847	161.0	162.0	1.87	12	1.0	0.0	0.0	0.1	2	184
BOU-DD26-847	168.5	169.4	0.25	46	0.9	0.0	1.3	2.7	209	153
BOU-DD26-847	193.4	201.6	0.47	246	8.2	0.0	3.6	2.3	352	410
Including	194.3	195.6	2.15	1,155	1.3	0.1	16.4	5.7	680	1,789
BOU-DD26-847	204.2	209.0	0.61	242	4.8	0.0	3.1	4.5	292	454
Including	205.8	208.0	1.08	438	2.2	0.1	6.1	8.2	389	827
BOU-DD26-847	213.4	214.3	0.08	33	0.9	0.0	0.6	1.5	51	84
BOU-DD26-848	259.7	284.0	0.61	239	24.3	0.1	1.9	2.6	296	392
Including	265.6	275.6	1.08	488	10.0	0.1	3.9	5.2	170	776
BOU-DD26-848	290.0	291.0	0.29	46	1.0	0.0	0.3	0.7	33	92
BOU-DD26-848	319.6	320.2	0.34	69	0.6	0.0	1.7	2.1	13	175
BOU-DD26-849	308.7	309.7	0.63	13	1.0	0.0	0.2	0.4	5	81
BOU-DD26-849	317.7	320.2	0.46	156	2.5	0.2	1.7	5.9	25	361
BOU-DD26-849	331.6	341.5	0.43	63	9.9	0.1	0.7	1.4	257	152
BOU-DD26-849	345.0	354.5	0.38	34	9.5	0.0	0.5	2.5	71	132
BOU-DD26-849	361.0	362.0	0.37	23	1.0	0.0	0.3	1.0	28	83
BOU-DD26-849	372.8	373.5	0.30	34	0.7	0.0	0.1	0.0	18	64
BOU-DD26-850	89.7	90.7	2.71	63	1.0	0.1	0.1	0.4	11	321
BOU-DD26-850	158.0	158.6	0.57	16	0.6	0.0	0.7	0.9	6	98
BOU-DD26-850	159.6	160.2	0.49	19	0.6	0.0	0.3	0.4	13	78
BOU-DD26-850	162.9	164.7	0.27	52	1.8	0.0	2.1	1.4	11	147
BOU-DD26-850	167.3	167.8	0.56	28	0.5	0.0	0.5	1.7	14	124
BOU-DD26-850	176.9	177.6	0.31	26	0.7	0.0	1.3	1.5	6	108
BOU-DD26-850	206.0	207.0	0.08	105	1.0	1.5	0.7	0.2	29	248
BOU-DD26-850	336.8	337.6	0.79	12	0.8	0.0	0.1	0.1	6	87
BOU-DD26-850	484.7	485.3	0.43	27	0.6	0.1	0.3	0.6	2	90
BOU-DD26-851	145.5	146.0	0.63	83	0.5	0.0	3.6	6.5	9	340
BOU-DD26-851	211.6	212.5	0.56	8	0.9	0.0	0.2	1.2	74	89
BOU-DD26-851	213.4	214.3	0.39	15	0.9	0.0	0.9	1.8	14	105
BOU-DD26-851	219.0	220.0	0.54	14	1.0	0.0	0.7	1.5	15	107
BOU-DD26-852	381.0	382.0	0.71	4	1.0	0.0	0.1	0.0	12	70
BOU-DD26-852	391.5	393.1	0.94	39	1.6	0.2	0.2	0.1	15	143
BOU-DD26-852	397.0	398.0	0.61	14	1.0	0.0	0.1	2.2	24	116
BOU-DD26-852	399.9	405.4	0.48	24	5.5	0.0	0.1	0.2	8	74
BOU-DD26-852	419.6	420.1	1.08	51	0.5	0.0	0.5	7.4	7	310
BOU-DD26-852	443.6	444.4	0.89	55	0.8	0.0	0.7	4.8	18	248
BOU-DD26-852	445.2	446.2	0.47	25	1.0	0.0	0.3	0.8	13	91
BOU-DD26-852	447.2	448.2	0.20	38	1.0	0.1	0.3	0.1	20	73
BOU-DD26-852	449.2	461.6	0.63	21	12.4	0.0	0.3	0.8	16	102
BOU-DD26-852	466.1	468.0	0.83	26	1.9	0.0	0.0	0.0	7	103
BOU-DD26-852	471.0	472.0	1.97	20	1.0	0.0	0.1	0.0	8	199
BOU-DD26-852	516.7	518.2	1.17	58	1.5	0.0	1.6	5.0	11	298
BOU-DD26-853	214.4	215.1	1.89	24	0.7	0.1	1.5	3.3	5	293
BOU-DD26-853	216.0	217.0	0.45	22	1.0	0.0	1.0	0.9	6	104
BOU-DD26-853	228.7	230.3	1.07	79	1.6	0.2	4.5	5.4	2	381
BOU-DD26-854	384.0	385.0	0.03	87	1.0	0.1	0.0	0.0	1	95
BOU-DD26-854	545.6	546.1	0.42	17	0.5	0.0	0.1	0.1	6	59
BOU-DD26-854	619.0	619.8	0.72	11	0.8	0.1	1.0	2.3	6	145
BOU-DD26-855	216.0	217.0	0.62	5	1.0	0.0	0.0	0.4	7	72
BOU-DD26-855	238.8	243.3	0.87	39	4.5	0.0	1.4	4.4	28	238
BOU-DD26-855	247.3	248.0	0.68	66	0.7	0.1	1.4	5.0	30	267
BOU-DD26-856	257.5	258.0	0.56	29	0.5	0.1	0.1	0.4	2	99
BOU-DD26-857	0.0	756.0								NSR
BOU-DD26-858	136.4	138.6	0.14	134	2.2	0.5	0.3	6.3	7	320
BOU-DD26-858	257.4	258.0	2.25	16	0.6	0.0	0.1	0.1	8	225
BOU-DD26-858	277.0	277.8	0.52	12	0.8	0.0	0.1	0.4	2	71
BOU-DD26-858	293.3	293.9	2.51	167	0.6	0.2	2.6	3.4	2	526
BOU-DD26-858	300.0	301.6	3.75	58	1.6	0.1	0.2	0.3	3	414
BOU-DD26-858	318.5	319.1	1.94	8	0.6	0.0	0.0	0.1	0	186
BOU-DD26-859	43.1	43.6	0.30	30	0.5	0.0	1.1	1.5	6	110
BOU-DD26-859	94.0	95.0	0.52	20	1.0	0.0	0.3	1.8	2	109
BOU-DD26-859	99.0	104.4	1.06	101	5.4	0.1	0.3	1.6	2	239
BOU-DD26-860	159.5	160.8	0.43	122	1.3	0.0	1.9	1.3	32	223
BOU-DD26-860	162.4	165.0	0.17	50	2.6	0.0	0.8	1.3	58	109
BOU-DD26-861	213.8	217.9	1.06	794	4.1	0.1	1.8	4.2	605	1,030
Including	216.0	217.0	1.90	2,477	1.0	0.4	3.2	3.4	997	2,827
BOU-DD26-861	230.3	231.0	0.26	40	0.7	0.0	0.9	4.7	15	178
BOU-DD26-861	284.6	286.5	0.07	115	1.9	0.0	3.1	1.8	11	220
BOU-DD26-862	10.0	11.0	0.03	79	1.0	0.0	0.3	0.1	23	89
BOU-DD26-862	58.2	59.0	0.39	46	0.8	0.1	0.3	1.0	4	111
BOU-DD26-862	326.3	327.7	0.83	7	1.4	0.0	0.0	0.0	2	85
BOU-DD26-862	337.1	342.7	1.46	86	5.6	0.1	0.5	1.2	2	258
BOU-DD26-862	414.1	414.6	0.14	47	0.5	0.0	3.8	2.8	0	192
BOU-DD26-862	445.0	445.9	1.15	0	0.9	0.0	0.0	0.0	6	105
BOU-DD26-863	71.6	72.6	0.60	38	1.0	0.0	0.7	0.4	3	113
BOU-DD26-863	301.9	302.4	0.71	12	0.5	0.0	0.1	0.1	6	81
BOU-DD26-863	399.9	400.4	0.48	18	0.5	0.0	0.0	0.1	4	64
BOU-DD26-864	268.0	269.0	0.03	44	1.0	0.0	0.0	0.0	4	47
BOU-DD26-865	80.8	81.6	0.72	31	0.8	0.1	0.6	3.5	9	182
BOU-DD26-865	162.1	162.6	1.67	46	0.5	0.1	1.7	4.9	9	335
BOU-DD26-865	169.0	170.0	0.68	27	1.0	0.0	0.2	1.7	3	128
BOU-DD26-865	175.4	175.9	0.19	45	0.5	0.0	3.3	3.6	2	198
BOU-DD26-866	283.0	284.0	0.62	8	1.0	0.0	0.0	0.0	9	65
BOU-DD26-866	291.0	292.0	0.68	9	1.0	0.0	0.0	0.0	14	72
BOU-DD26-866	414.0	415.0	0.84	4	1.0	0.0	0.0	0.0	5	80
BOU-DD26-866	418.0	418.6	6.46	70	0.6	0.0	2.5	11.6	45	936
BOU-DD26-866	448.6	451.3	0.85	10	2.7	0.0	0.1	0.1	40	89
BOU-DD26-867	327.4	327.9	2.54	67	0.5	0.1	0.2	1.2	25	329
BOU-DD26-867	477.0	478.3	1.97	196	1.3	0.1	6.5	2.4	29	547
BOU-DD26-867	487.0	489.0	0.28	238	2.0	0.1	1.0	1.8	612	332
BOU-DD26-868	152.0	152.6	1.33	63	0.6	0.1	0.1	0.1	9	197
BOU-DD26-868	449.5	451.2	1.58	42	1.7	0.1	0.1	0.2	5	193
BOU-DD26-869	0.0	600.0								NSR
BOU-DD26-870	101.8	102.7	0.41	18	0.9	0.2	0.5	0.0	33	81
BOU-DD26-871	187.6	188.1	1.72	35	0.5	0.1	2.3	0.8	4	253
BOU-DD26-872	0.0	339.0								NSR
BOU-DD26-873	107.4	108.0	0.37	27	0.6	0.0	0.3	0.9	7	85
BOU-DD26-873	170.8	171.6	0.06	60	0.8	0.1	1.2	8.0	13	256
BOU-DD26-873	175.0	175.6	0.03	63	0.6	4.3	2.1	0.6	10	451
BOU-DD26-873	211.2	211.7	0.98	10	0.5	0.0	0.1	0.2	5	105
BOU-DD26-873	219.0	219.5	0.88	32	0.5	0.1	0.1	3.4	5	190
BOU-DD26-873	221.4	223.0	1.03	33	1.6	0.1	0.1	1.3	7	159
BOU-DD26-874	192.4	193.0	0.30	36	0.6	0.0	1.8	8.2	2	267
BOU-DD26-874	241.8	244.7	1.36	23	2.9	0.0	0.1	1.3	3	176
BOU-DD26-875	117.0	118.0	0.89	1	1.0	0.0	0.0	0.0	11	82
BOU-DD26-875	324.7	325.2	1.53	15	0.5	0.0	0.1	0.0	2	157
BOU-DD26-875	346.1	348.5	1.33	20	2.4	0.0	0.1	0.2	17	148
BOU-DD26-875	405.0	407.0	0.41	26	2.0	0.0	0.1	0.1	61	66
BOU-DD26-876	17.0	18.0	0.92	11	1.0	0.0	0.4	0.3	4	107
BOU-DD26-876	66.0	67.0	1.71	26	1.0	0.1	0.8	0.5	5	210
BOU-DD26-876	265.9	266.8	0.85	39	0.9	0.1	0.1	0.1	5	125
BOU-DD26-877	102.9	103.8	0.31	20	0.9	0.0	0.8	0.2	5	69
BOU-DD26-878	349.7	350.2	2.12	53	0.5	0.3	0.2	0.8	53	284
BOU-DD26-878	423.4	424.1	2.17	23	0.7	0.0	0.2	0.2	66	229
BOU-DD26-878	474.9	475.4	0.48	33	0.5	0.0	0.2	0.2	13	87
BOU-DD26-878	556.9	557.6	1.06	29	0.7	0.0	0.7	1.8	10	176
BOU-DD26-880	286.0	286.5	1.09	22	0.5	0.1	0.4	0.9	2	151
BOU-DD26-880	321.1	323.0	1.40	37	1.9	0.1	0.2	0.8	5	190
BOU-DD26-881	427.2	428.1	2.51	34	0.9	0.2	0.4	9.1	22	468
BOU-DD26-881	432.1	434.8	0.55	19	2.7	0.3	0.2	3.9	12	174
BOU-DD26-881	501.0	502.0	0.60	6	1.0	0.0	0.1	0.0	6	63
BOU-DD26-882	86.0	86.7	0.52	19	0.7	0.0	1.0	1.3	8	113
BOU-DD26-882	191.2	192.5	2.01	32	1.3	0.8	0.1	0.2	10	283
BOU-DD26-882	383.9	384.7	0.65	16	0.8	0.0	0.1	0.2	11	82
BOU-DD26-882	386.5	387.5	0.67	21	1.0	0.1	0.0	0.0	7	88
BOU-DD26-882	389.7	390.2	0.54	8	0.5	0.0	0.0	0.8	8	77
BOU-DD26-883	148.0	150.0	1.78	5	2.0	0.0	0.0	0.0	3	165
BOU-DD26-883	192.7	194.5	0.59	18	1.8	0.1	0.3	0.5	155	100
BOU-DD26-883	214.0	215.0	0.42	37	1.0	0.0	0.1	0.1	84	80
BOU-DD26-883	220.0	221.0	0.37	31	1.0	0.0	0.1	1.5	178	99
BOU-DD26-883	249.0	264.2	1.05	319	15.2	0.0	3.5	5.3	153	593
Including	249.8	254.0	1.81	586	4.2	0.1	6.2	8.1	128	1,038
BOU-DD26-883	332.6	340.0	0.41	34	7.4	0.0	0.5	0.9	5	100
BOU-DD26-884	40.1	43.1	1.76	28	3.0	0.0	0.4	4.6	14	288
BOU-DD26-884	63.6	65.3	1.46	29	1.7	0.0	0.8	3.3	7	243
BOU-DD26-884	66.2	67.1	0.33	21	0.9	0.0	1.1	2.1	6	116
BOU-DD26-884	231.2	231.7	1.75	26	0.5	0.2	0.1	0.1	15	202
BOU-DD26-885	0.0	156.0								NSR
BOU-DD26-886	36.4	38.0	0.62	31	1.6	0.1	0.2	3.6	8	168
BOU-DD26-886	70.8	71.5	0.52	14	0.7	0.0	0.1	0.0	7	65
BOU-DD26-886	73.0	74.0	2.13	79	1.0	0.1	0.2	0.1	8	287
BOU-DD26-887	430.8	433.2	1.81	189	2.4	0.2	0.4	0.5	4	380
BOU-DD26-887	454.3	454.8	0.47	20	0.5	0.1	0.4	1.4	4	102
BOU-DD26-887	455.3	455.8	2.25	42	0.5	0.2	0.3	1.2	4	286
BOU-DD26-888	0.0	630.0								NSR
BOU-DD26-889	29.0	30.0	0.03	62	1.0	0.4	0.2	0.4	2	104
BOU-DD26-889	151.3	152.2	0.65	44	0.9	0.0	0.2	0.1	141	111
BOU-DD26-889	159.7	160.2	1.15	36	0.5	0.0	0.1	0.6	94	156
BOU-DD26-890	126.6	127.1	0.79	59	0.5	0.1	0.4	2.0	137	185
BOU-DD26-890	211.5	212.0	0.25	35	0.5	0.0	0.1	0.0	318	65
BOU-DD26-890	401.5	402.5	0.06	83	1.0	0.0	0.0	0.0	0	89
BOU-DD26-891	55.4	55.9	1.89	42	0.5	0.1	1.5	3.4	5	311
BOU-DD26-891	155.0	156.0	0.03	54	1.0	0.0	0.4	0.5	0	75
BOU-DD26-891	157.0	158.0	0.03	57	1.0	0.0	0.3	1.1	1	90
BOU-DD26-891	183.5	184.7	0.52	50	1.2	0.1	0.1	0.2	4	109
BOU-DD26-891	196.0	197.0	0.03	53	1.0	0.0	0.2	0.2	4	65
BOU-DD26-892	87.4	88.3	0.07	54	0.9	0.0	0.9	0.2	9	81
BOU-DD26-892	93.8	95.6	0.58	38	1.8	0.1	0.1	0.1	9	102
BOU-DD26-892	101.7	102.2	1.29	20	0.5	0.0	0.1	0.0	5	140
BOU-DD26-892	199.0	199.9	0.71	12	0.9	0.0	0.3	0.2	2	86
BOU-DD26-892	200.8	201.7	0.43	21	0.9	0.1	0.1	2.2	3	109
BOU-DD26-892	210.1	210.6	2.25	35	0.5	0.1	0.1	1.1	2	269
BOU-DD26-892	220.0	220.8	1.10	47	0.8	0.2	0.1	0.3	0	171
BOU-DD26-893	0.0	156.0								NSR
BOU-DD26-894	224.4	226.4	0.53	25	2.0	0.0	0.0	0.1	606	86
BOU-DD26-894	233.9	235.1	1.70	78	1.2	0.0	0.2	0.1	315	242
BOU-DD26-894	236.6	237.3	0.72	3	0.7	0.0	0.0	0.0	3	68
BOU-DD26-894	250.7	251.6	0.72	9	0.9	0.0	0.0	0.0	92	77
BOU-DD26-894	303.0	309.6	0.60	94	6.6	0.0	1.0	2.0	262	213
BOU-DD26-894	315.7	319.9	0.40	30	4.2	0.0	0.2	0.9	65	90
BOU-DD26-894	322.6	323.4	0.46	15	0.8	0.0	0.4	0.2	45	69
BOU-DD26-894	324.2	329.7	1.55	55	5.5	0.1	0.5	2.7	33	266
Including	324.7	327.9	2.05	66	3.2	0.1	0.8	3.0	43	332
BOU-DD26-894	385.1	385.6	0.57	29	0.5	0.0	0.1	0.3	3	89
BOU-DD26-894	434.1	434.9	0.03	50	0.8	0.1	0.1	0.2	10	63
BOU-DD26-894	463.0	464.0	1.13	3	1.0	0.0	0.0	0.0	6	106
BOU-DD26-895	33.0	34.0	0.68	30	1.0	0.0	1.1	1.4	0	144
BOU-DD26-895	39.0	40.0	0.49	21	1.0	0.0	1.2	1.1	2	113
BOU-DD26-895	134.5	135.0	1.92	26	0.5	0.1	0.2	0.0	3	207
BOU-DD26-895	261.2	261.8	1.86	26	0.6	0.1	0.2	0.3	3	207
BOU-DD26-895	269.1	271.3	1.44	151	2.2	0.3	0.2	4.9	2	409
BOU-DD26-896	74.5	75.1	0.39	44	0.6	0.1	0.5	2.9	5	154
BOU-DD26-896	136.8	138.0	0.58	75	1.2	0.0	0.7	1.6	4	176
BOU-DD26-896	141.5	142.4	0.06	154	0.9	0.4	1.6	0.3	5	224
BOU-DD26-896	265.6	266.5	0.59	9	0.9	0.0	0.2	1.6	0	100
BOU-DD26-896	286.2	286.7	1.25	18	0.5	0.1	0.3	1.4	2	170
BOU-DD26-897	329.9	330.4	0.43	30	0.5	0.0	0.2	0.6	6	85
BOU-DD26-897	353.5	354.0	1.54	30	0.5	0.1	0.1	0.1	33	175
BOU-DD26-897	374.6	375.2	0.26	35	0.6	0.3	0.1	0.0	6	82
BOU-DD26-897	376.0	376.8	0.58	20	0.8	0.0	0.1	0.0	8	77
BOU-DD26-897	415.6	416.4	0.16	43	0.8	0.3	0.0	0.0	14	80
BOU-DD26-897	532.9	533.4	0.56	10	0.5	0.1	0.5	0.2	5	80
BOU-DD26-897	558.8	559.5	0.60	6	0.7	0.0	0.2	0.0	4	64
BOU-DD26-898	367.0	368.0	0.21	54	1.0	0.0	0.2	0.0	16	78
BOU-DD26-898	403.0	404.0	0.45	45	1.0	0.1	1.5	0.1	32	121
BOU-DD26-898	445.6	446.1	0.48	25	0.5	0.1	0.1	0.1	1	78
BOU-DD26-898	508.0	509.0	0.37	16	1.0	0.0	0.1	1.1	4	75
BOU-DD26-898	511.5	513.5	1.56	28	2.0	0.4	0.1	0.1	8	205
BOU-DD26-898	521.4	522.0	0.46	15	0.6	0.0	0.2	0.1	23	66
BOU-DD26-898	558.0	559.0	0.03	129	1.0	0.2	0.2	0.2	5	155
BOU-DD26-898	570.7	571.6	1.17	39	0.9	0.1	0.8	0.2	12	172
BOU-DD26-898	618.5	619.5	0.77	25	1.0	0.1	0.4	0.3	17	112
BOU-DD26-899	41.6	42.1	0.10	44	0.5	0.1	1.9	4.1	2	179
BOU-DD26-899	42.9	43.5	0.28	42	0.6	0.0	1.8	2.3	0	149
BOU-DD26-899	57.2	61.5	1.14	48	4.3	0.1	0.1	1.6	3	188
BOU-DD26-899	132.6	133.2	1.07	25	0.6	0.0	0.2	1.2	2	153
BOU-DD26-899	156.2	158.7	2.37	221	2.5	0.2	0.6	1.1	4	479
BOU-DD26-900	14.8	15.6	0.03	49	0.8	0.0	0.0	0.0	3	52
BOU-DD26-900	20.4	21.2	0.03	50	0.8	0.0	0.0	0.0	3	53
BOU-DD26-900	34.0	35.0	0.03	126	1.0	0.0	0.0	0.0	19	129
BOU-DD26-900	253.0	267.0	1.00	85	14.0	0.1	0.8	3.2	135	268
Including	255.0	258.6	1.40	124	3.6	0.3	1.2	6.0	36	421
BOU-DD26-900	283.0	283.8	0.35	28	0.8	0.1	0.2	0.5	96	78
BOU-DD26-901	375.0	376.0	0.64	15	1.0	0.0	0.0	0.0	12	77
BOU-DD26-901	377.0	378.0	0.75	11	1.0	0.1	0.1	0.0	12	85
BOU-DD26-901	434.9	435.8	0.48	149	0.9	0.1	0.1	0.0	4	204
BOU-DD26-901	440.3	443.8	1.01	134	3.5	0.1	0.9	3.4	20	317
Including	440.3	442.3	1.61	200	2.0	0.1	0.9	4.6	25	464
BOU-DD26-901	446.8	467.5	0.55	54	20.7	0.0	0.7	1.9	32	160
Including	447.8	450.3	1.02	100	2.5	0.0	1.5	4.1	15	308
BOU-DD26-902	6.0	6.8	1.04	56	0.8	0.0	0.7	0.0	11	165
BOU-DD26-902	60.5	61.4	0.43	24	0.9	0.0	0.1	0.0	5	65
BOU-DD26-903	158.0	159.0	0.60	15	1.0	0.0	0.2	2.0	4	115
BOU-DD26-903	159.9	161.7	1.06	33	1.8	0.1	0.5	2.5	5	195
BOU-DD26-903	167.3	168.6	1.61	22	1.3	0.1	0.4	0.5	6	190
BOU-DD26-903	319.2	319.8	2.74	18	0.6	0.1	0.1	0.0	4	269
BOU-DD26-903	320.9	323.0	2.67	42	2.1	0.1	0.1	0.0	8	288
BOU-DD26-904	86.8	91.2	1.09	12	4.4	0.0	0.2	0.5	4	124
BOU-DD26-904	224.0	225.0	0.76	14	1.0	0.0	0.4	1.3	3	117
BOU-DD26-904	265.8	266.7	0.36	39	0.9	0.0	0.6	2.7	3	138
BOU-DD26-906	28.8	29.7	0.03	47	0.9	0.1	4.5	0.0	51	146
BOU-DD26-907	124.0	125.0	0.03	59	1.0	0.0	0.0	0.0	2	65
BOU-DD26-907	127.0	128.0	0.03	518	1.0	0.0	0.0	0.0	0	521
BOU-DD26-907	459.4	459.9	1.18	63	0.5	0.0	0.5	1.0	9	201
BOU-DD26-907	497.9	498.5	0.61	6	0.6	0.0	0.0	0.0	2	64
BOU-DD26-907	531.9	532.4	0.57	17	0.5	0.1	0.4	0.2	7	84
BOU-DD26-907	560.9	561.9	0.82	42	1.0	0.0	0.8	1.6	22	165
BOU-DD26-907	606.6	607.6	0.03	86	1.0	0.0	0.0	0.0	3	92
BOU-DD26-907	663.1	664.4	0.70	25	1.3	0.9	2.8	0.2	16	211
BOU-DD26-907	665.0	665.5	0.69	13	0.5	0.0	0.4	0.0	21	86
BOU-DD26-907	666.5	667.0	0.50	14	0.5	0.0	0.6	0.5	28	83
BOU-DD26-907	668.0	671.3	0.55	18	3.3	0.1	0.9	0.2	15	98
BOU-DD26-907	694.1	695.0	0.74	35	0.9	0.0	0.2	0.2	4	111
BOU-DD26-908	117.2	118.4	3.00	48	1.2	0.2	0.7	2.3	7	390
BOU-DD26-908	279.6	281.6	0.50	20	2.0	0.0	0.7	1.4	3	109
BOU-DD26-908	404.6	408.2	1.96	33	3.6	0.1	0.1	0.1	4	221
Including	406.6	408.2	2.90	40	1.6	0.2	0.0	0.0	7	315
BOU-DD26-909	14.7	17.7	0.52	19	3.0	0.1	0.6	0.0	7	83
BOU-DD26-909	18.6	19.4	0.54	7	0.8	0.0	1.4	0.3	6	89
BOU-DD26-909	22.0	23.0	0.03	77	1.0	0.0	6.6	1.4	4	232
BOU-DD26-909	125.8	126.6	0.58	5	0.8	0.0	0.1	0.3	3	66
BOU-DD26-909	280.9	281.8	0.09	52	0.9	0.0	0.3	1.2	4	89
BOU-DD26-909	287.6	289.4	0.73	99	1.8	0.3	3.8	3.0	73	325
BOU-DD26-909	290.3	291.2	0.56	19	0.9	0.0	0.6	0.3	12	90
BOU-DD26-909	428.8	430.3	2.49	72	1.5	0.1	0.1	0.1	6	308
Including	428.8	429.3	4.76	186	0.5	0.2	0.1	0.1	5	633
BOU-DD26-909	432.7	433.3	1.65	19	0.6	0.1	0.0	0.2	5	178
BOU-DD26-910	424.6	425.4	0.59	4	0.8	0.0	0.0	0.0	16	58
BOU-DD26-910	456.5	457.0	0.54	34	0.5	0.0	0.3	0.0	16	89
BOU-DD26-911	221.0	221.8	0.18	58	0.8	0.0	0.1	0.0	17	80
BOU-DD26-911	356.6	357.1	0.61	46	0.5	0.0	0.6	1.5	95	146
BOU-DD26-911	365.0	365.6	0.29	49	0.6	0.0	0.1	0.1	38	83
BOU-DD26-911	377.2	378.1	0.14	53	0.9	0.1	0.0	0.0	9	73
BOU-DD26-911	392.2	393.1	0.83	19	0.9	0.1	0.7	0.4	14	120
BOU-DD26-911	425.4	426.4	0.03	57	1.0	0.1	0.0	0.5	7	78
BOU-DD26-911	436.7	437.5	1.70	41	0.8	0.0	1.1	1.8	25	255
BOU-DD26-912	344.4	346.0	0.79	30	1.6	0.1	0.1	0.7	18	121
BOU-DD26-913	17.1	18.1	0.42	48	1.0	0.1	2.2	3.3	5	198
BOU-DD26-913	34.0	35.0	0.32	192	1.0	0.4	4.2	4.3	7	420
BOU-DD26-913	37.0	37.9	0.24	51	0.9	0.1	1.6	2.3	9	154
BOU-DD26-913	51.0	53.0	0.20	36	2.0	0.0	1.6	1.2	1	111
BOU-DD26-913	110.0	110.6	1.44	39	0.6	0.1	0.1	4.4	7	267
BOU-DD26-914	26.6	27.4	1.12	9	0.8	0.0	0.5	0.6	3	131
BOU-DD26-914	30.3	30.8	3.26	59	0.5	0.0	2.5	3.4	5	470
BOU-DD26-914	44.0	45.0	0.17	43	1.0	0.0	0.9	1.0	2	96
BOU-DD26-914	57.0	59.0	1.05	10	2.0	0.0	0.5	0.9	0	134
BOU-DD26-914	103.0	106.0	0.56	49	3.0	0.1	2.3	2.9	41	209
BOU-DD26-914	156.6	157.5	0.86	16	0.9	0.0	0.1	2.1	9	140
BOU-DD26-914	175.4	175.9	0.46	43	0.5	0.0	0.3	1.4	3	120
BOU-DD26-914	178.6	179.1	3.18	325	0.5	0.2	0.1	0.3	7	630
BOU-DD26-914	227.0	228.3	0.41	18	1.3	0.1	0.1	0.1	8	64
BOU-DD26-914	272.5	273.0	1.66	32	0.5	0.1	0.5	2.6	4	252
BOU-DD26-915	51.0	52.0	1.58	19	1.0	0.0	0.6	1.1	3	197
BOU-DD26-915	92.0	93.0	0.64	5	1.0	0.0	0.2	0.4	3	76
BOU-DD26-915	103.0	103.5	0.81	17	0.5	0.0	0.5	3.3	10	171
BOU-DD26-915	121.5	122.5	0.55	87	1.0	0.0	5.9	1.4	4	278
BOU-DD26-915	139.7	140.3	0.10	43	0.6	0.1	1.0	2.6	7	131
BOU-DD26-915	155.9	156.8	0.33	30	0.9	0.0	0.4	1.4	11	98
BOU-DD26-915	160.4	161.3	5.47	15	0.9	0.0	0.4	0.4	9	522
BOU-DD26-915	208.3	213.2	1.36	25	4.9	0.0	0.0	0.1	19	153
Including	212.4	213.2	3.16	60	0.8	0.1	0.1	0.2	20	356
BOU-DD26-915	224.0	225.0	0.97	7	1.0	0.0	0.0	0.3	3	101
BOU-DD26-915	244.3	246.0	1.32	50	1.7	0.1	0.1	0.4	5	189
BOU-DD26-915	414.0	414.5	0.77	48	0.5	0.2	0.7	1.3	6	170
BOU-DD26-916	489.4	490.2	0.71	78	0.8	0.0	0.1	0.0	10	147
BOU-DD26-916	492.7	493.2	0.34	22	0.5	0.0	0.2	0.1	30	59
BOU-DD26-916	493.8	494.4	0.38	19	0.6	0.0	0.1	1.1	7	79
BOU-DD26-916	496.2	497.2	0.93	53	1.0	0.0	1.3	4.3	12	250
BOU-DD26-916	504.2	504.7	0.51	50	0.5	0.2	0.2	0.2	8	117
BOU-DD26-916	527.1	529.0	0.68	17	1.9	0.1	0.1	0.1	9	87
BOU-DD26-917	110.5	111.5	0.86	8	1.0	0.0	0.3	0.5	4	102
BOU-DD26-917	128.8	129.5	2.27	33	0.7	0.1	0.1	1.0	6	262
BOU-DD26-917	150.7	154.8	2.27	129	4.1	0.3	0.1	0.2	7	364
Including	151.7	152.7	4.75	170	1.0	0.3	0.1	0.1	11	627
BOU-DD26-917	230.0	232.4	1.14	20	2.4	0.0	0.6	0.5	8	148
BOU-DD26-918	0.0	201.0								NSR
BOU-DD26-919	155.6	157.0	1.21	34	1.4	0.0	1.3	3.4	11	240
BOU-DD26-920	171.8	172.3	0.76	17	0.5	0.0	0.1	0.1	38	88
BOU-DD26-920	187.3	187.8	0.52	72	0.5	0.0	0.2	0.9	878	157
BOU-DD26-920	215.5	223.5	0.51	204	8.0	0.0	2.9	3.3	199	378
Including	218.5	219.8	0.87	652	1.3	0.0	13.9	10.4	534	1,213
BOU-DD26-920	235.0	236.0	0.37	24	1.0	0.0	0.0	2.9	107	121
BOU-DD26-920	256.0	256.6	0.74	60	0.6	0.0	0.2	2.5	89	182
BOU-DD26-920	258.1	258.8	0.32	28	0.7	0.0	0.4	1.2	52	90
BOU-DD26-0921	205.0	206.0	2.17	4	1.0	0.0	0.3	0.7	3	220
BOU-DD26-0921	246.1	246.6	6.30	474	0.5	0.9	0.2	0.0	5	1,112
BOU-DD26-0921	250.9	252.7	1.78	72	1.8	0.1	3.6	3.3	6	371
BOU-DD26-0921	293.1	294.0	0.53	20	0.9	0.0	0.7	1.3	6	108
BOU-DD26-0921	364.7	365.4	0.03	63	0.7	0.4	0.3	0.4	6	111
BOU-DD26-0921	366.2	368.0	0.75	31	1.8	0.1	0.2	0.3	6	114
BOU-DD26-0921	458.0	458.5	0.64	2	0.5	0.0	0.6	0.9	2	91
BOU-DD26-0922	23.0	24.0	1.10	8	1.0	0.0	0.2	0.2	1	114
BOU-DD26-0922	75.0	76.0	0.37	22	1.0	0.0	0.6	0.5	5	78
BOU-DD26-0922	180.7	181.4	0.66	35	0.7	0.0	1.6	2.3	5	174
BOU-DD26-0922	200.0	200.9	0.90	5	0.9	0.1	0.5	1.3	3	125
BOU-DD26-0922	268.0	268.9	0.45	37	0.9	0.0	0.7	2.0	4	131
BOU-DD26-0922	286.0	286.9	0.07	50	0.9	0.0	0.2	0.4	1	69
BOU-DD26-0922	324.0	325.0	0.64	5	1.0	0.0	0.2	0.9	4	85
BOU-DD26-0923	324.3	325.8	1.53	25	1.5	0.0	0.1	0.5	7	177
BOU-DD26-0923	333.0	334.0	0.52	12	1.0	0.0	0.1	0.6	7	74
BOU-DD26-0923	391.7	392.2	0.46	35	0.5	0.3	1.5	2.9	11	183
BOU-DD26-0923	432.3	433.2	0.03	78	0.9	2.8	0.0	0.0	11	304
BOU-DD26-0924	198.6	200.2	0.54	52	1.6	0.1	0.7	2.5	460	176
BOU-DD26-0924	213.3	213.9	1.34	26	0.6	0.1	0.5	0.5	135	175
BOU-DD26-0924	226.0	227.0	0.32	60	1.0	0.0	2.7	2.4	12	190
BOU-DD26-0925	319.5	320.1	0.51	27	0.6	0.0	0.3	0.1	8	82
BOU-DD26-0925	339.1	340.0	1.22	69	0.9	0.1	4.8	7.9	24	436
BOU-DD26-0925	346.0	348.0	0.72	10	2.0	0.1	0.3	0.1	7	87
BOU-DD26-0925	358.0	359.0	0.79	8	1.0	0.0	0.3	0.0	4	87
BOU-DD26-0925	480.6	483.2	0.63	18	2.6	0.1	0.1	0.1	9	89
BOU-DD26-0925	490.8	491.5	0.91	15	0.7	0.1	0.2	0.1	44	108
BOU-DD26-0926	114.0	119.5	0.47	33	5.5	0.0	0.5	0.3	35	93
Including	114.0	115.4	1.31	61	1.4	0.0	0.4	0.4	86	198
BOU-DD26-0926	124.1	134.0	0.45	173	9.9	0.0	0.7	1.7	16	265
Including	128.0	131.0	1.02	423	3.0	0.1	1.0	3.3	13	608
BOU-DD26-0927	0.0	201.0								NSR
BOU-DD26-0928	63.2	64.4	0.13	43	1.2	0.0	1.4	0.5	29	95
BOU-DD26-0928	68.0	68.5	0.45	39	0.5	0.0	0.6	0.4	7	100
BOU-DD26-0928	103.5	104.0	0.92	20	0.5	0.1	1.7	0.7	14	154
BOU-DD26-0928	207.4	211.6	0.91	57	4.2	0.2	5.3	4.1	11	334
Including	208.0	210.3	1.54	66	2.3	0.2	4.0	4.9	16	395
BOU-DD26-0929	20.2	24.2	1.32	53	4.0	0.0	1.3	0.7	5	214
BOU-DD26-0929	41.7	53.5	1.76	50	11.8	0.1	0.5	0.5	3	234
Including	47.9	51.7	3.89	116	3.8	0.2	0.5	0.8	4	506
BOU-DD26-0929	62.4	63.4	0.14	170	1.0	0.1	2.8	7.2	12	388
BOU-DD26-0929	327.0	327.7	0.51	17	0.7	0.1	0.2	1.4	3	100
BOU-DD26-0929	408.5	409.0	1.76	35	0.5	0.2	0.8	3.2	4	286
BOU-DD26-0930	390.3	391.8	0.20	45	1.5	0.0	0.1	0.1	20	68
BOU-DD26-0930	403.6	406.2	0.93	22	2.6	0.1	0.1	0.1	17	118
BOU-DD26-0930	431.0	432.0	0.03	68	1.0	0.2	0.0	0.0	3	85
BOU-DD26-0930	475.0	475.5	1.31	38	0.5	0.1	0.2	0.1	15	172
BOU-DD26-0930	476.3	477.0	0.34	26	0.7	0.0	0.1	0.1	4	63
BOU-DD26-0930	489.7	490.4	0.84	42	0.7	0.5	0.2	0.1	94	163
BOU-DD26-0930	597.5	598.3	0.59	8	0.8	0.0	0.1	0.8	12	81
BOU-DD26-0930	599.1	599.7	0.34	27	0.6	0.1	0.3	0.1	18	71
BOU-DD26-0931	93.8	94.7	0.20	56	0.9	0.1	4.1	2.1	7	199
BOU-DD26-0931	125.5	133.5	1.46	25	8.0	0.1	0.2	0.4	10	175
BOU-DD26-0931	134.9	135.4	0.62	19	0.5	0.1	0.1	0.1	24	88
BOU-DD26-0932	531.5	532.5	0.49	15	1.0	0.0	0.1	0.1	1	63
BOU-DD26-0933	14.0	15.0	0.70	5	1.0	0.0	0.0	0.0	5	69
BOU-DD26-0933	17.0	18.0	0.80	9	1.0	0.0	0.0	0.0	5	82
BOU-DD26-0933	408.0	411.4	0.55	21	3.4	0.0	0.1	0.1	16	74
BOU-DD26-0934	55.2	55.8	0.83	33	0.6	0.0	0.3	3.1	9	178
BOU-DD26-0934	80.7	85.0	0.90	37	4.3	0.0	0.5	2.0	5	169
BOU-DD26-0935	5.2	6.7	1.10	40	1.5	0.0	0.9	0.4	8	164
BOU-DD26-0935	42.4	48.0	1.07	33	5.6	0.0	0.6	0.8	3	157
Including	42.4	45.0	1.60	56	2.6	0.0	0.8	1.0	3	236
BOU-DD26-0935	104.5	105.3	1.07	5	0.8	0.0	0.1	0.1	3	104
BOU-DD26-0936	0.0	210.0	0.00	0	210.0	0.0	0.0	0.0	0	0
BOU-DD26-0937	0.0	255.0	0.00	0	255.0	0.0	0.0	0.0	0	0
BOU-DD26-0938	220.6	221.8	1.29	18	1.2	0.1	0.4	0.9	18	164
BOU-DD26-0939	52.3	52.8	0.97	20	0.5	0.0	0.7	3.9	13	203
BOU-DD26-0939	57.5	59.2	1.20	21	1.7	0.0	0.7	0.2	3	147
BOU-DD26-0939	85.0	86.0	5.42	52	1.0	0.0	1.3	0.0	2	564
BOU-DD26-0939	88.0	88.6	0.89	40	0.6	0.0	0.8	3.0	7	198
BOU-DD26-0939	100.3	101.2	1.10	6	0.9	0.0	0.0	0.0	3	107
BOU-DD26-0939	205.0	206.0	0.03	73	1.0	0.0	0.0	0.0	5	76
BOU-DD26-0939	452.0	453.0	1.04	6	1.0	0.0	0.2	0.5	5	114
BOU-DD26-0939	468.0	469.0	0.38	16	1.0	0.0	1.0	1.2	3	96
BOU-DD26-0939	476.4	477.1	2.25	29	0.7	0.1	0.3	0.6	2	255
BOU-DD26-0939	483.4	487.4	1.16	9	4.0	0.0	0.1	0.2	4	123
BOU-DD26-0940	17.2	18.1	3.82	5	0.9	0.0	0.1	0.1	4	354
BOU-DD26-0940	118.5	120.0	0.46	21	1.5	0.0	0.1	1.5	19	98
BOU-DD26-0940	121.3	121.8	0.70	30	0.5	0.1	1.1	2.9	8	176
BOU-DD26-0940	123.0	123.5	1.11	23	0.5	0.0	0.3	2.7	11	186
BOU-DD26-0940	146.3	147.3	0.73	29	1.0	0.0	1.3	1.9	5	159
BOU-DD26-0940	151.3	152.3	0.73	12	1.0	0.0	0.8	1.2	7	118
BOU-DD26-0941	23.4	25.0	0.90	197	1.6	0.1	1.8	0.2	58	321
BOU-DD26-0941	29.0	30.9	0.22	255	1.9	0.1	2.5	0.1	145	331
BOU-DD26-0941	37.0	37.5	2.41	177	0.5	0.3	0.5	1.1	74	447
BOU-DD26-0941	60.3	64.3	1.01	87	4.0	0.0	1.1	1.7	84	237
Including	60.8	62.5	1.68	159	1.7	0.1	2.3	3.8	88	439
BOU-DD26-0941	92.4	98.3	0.94	99	5.9	0.0	2.0	3.4	191	298
Including	92.4	94.5	1.90	109	2.1	0.0	0.8	4.2	226	388
BOU-DD26-0941	101.9	102.7	0.21	35	0.8	0.0	1.0	1.5	8	104
BOU-DD26-0941	112.7	115.1	0.06	67	2.4	0.0	0.3	0.4	8	87
BOU-DD26-0941	148.2	148.7	0.07	48	0.5	0.0	4.3	0.4	8	145
BOU-DD26-0941	188.8	189.5	0.33	32	0.7	0.0	0.6	2.6	6	126
BOU-DD26-0941	191.3	192.2	0.52	23	0.9	0.1	0.0	0.1	8	76
BOU-DD26-0941	199.5	201.0	0.63	25	1.5	0.0	0.0	0.1	6	87
BOU-DD26-0941	203.6	204.3	0.72	6	0.7	0.0	0.1	0.0	3	72
BOU-DD26-0942	32.5	34.6	1.59	37	2.1	0.0	0.2	0.3	110	195
BOU-DD26-0942	168.0	168.7	1.10	33	0.7	0.1	0.3	5.4	12	253
BOU-DD26-0942	171.1	173.3	0.90	33	2.2	0.1	0.2	7.7	10	282
BOU-DD26-0942	180.9	182.6	0.79	46	1.7	0.0	2.5	4.0	5	247
BOU-DD26-0943	316.0	322.0	1.34	39	6.0	0.1	0.1	0.1	7	167
BOU-DD26-0944	428.0	428.7	0.52	81	0.7	0.3	1.6	0.2	17	182
BOU-DD26-0944	489.9	496.2	0.81	8	6.3	0.0	0.1	0.2	15	89
BOU-DD26-0944	497.8	498.4	0.74	8	0.6	0.1	0.1	0.2	11	87
BOU-DD26-0944	504.8	505.3	1.09	18	0.5	0.4	0.1	0.1	7	147
BOU-DD26-0945	33.7	35.7	0.71	93	2.0	0.0	1.6	2.7	24	243
BOU-DD26-0945	47.8	53.0	0.17	114	5.2	0.0	1.7	3.4	163	233
BOU-DD26-0945	155.0	155.6	0.45	20	0.6	0.0	0.3	0.8	9	85
BOU-DD26-0945	196.9	197.5	1.45	16	0.6	0.0	0.1	1.6	2	182
BOU-DD26-0945	200.2	201.1	0.77	9	0.9	0.0	0.2	0.4	1	91
BOU-DD26-0945	232.0	233.0	0.66	2	1.0	0.0	0.0	0.1	4	64
BOU-DD26-0946	17.0	18.0	0.06	51	1.0	0.0	0.1	0.0	18	60
BOU-DD26-0946	19.0	23.0	0.19	49	4.0	0.0	0.3	0.0	48	74
BOU-DD26-0946	36.0	37.0	0.37	37	1.0	0.1	0.4	1.0	301	113
BOU-DD26-0946	49.6	50.3	0.12	41	0.7	0.0	1.8	2.7	37	143
BOU-DD26-0946	51.7	58.7	0.61	115	7.0	0.0	0.6	2.3	79	230
BOU-DD26-0946	59.3	60.0	0.21	41	0.7	0.0	0.7	0.9	132	94
BOU-DD26-0947	40.8	41.3	0.64	80	0.5	0.0	4.1	3.3	5	283
BOU-DD26-0947	73.5	84.7	1.10	13	11.2	0.0	0.3	0.9	4	138
Including	73.5	76.9	2.44	11	3.4	0.0	0.2	0.8	3	250
BOU-DD26-0948	6.8	12.4	1.13	10	5.6	0.0	0.0	0.0	5	114
Including	10.6	11.8	2.89	20	1.2	0.0	0.1	0.1	9	282
BOU-DD26-0948	99.9	100.8	0.93	2	0.9	0.0	0.5	1.2	4	121
BOU-DD26-0949	191.5	192.4	0.40	19	0.9	0.0	0.5	0.8	14	81
BOU-DD26-0949	300.0	300.8	2.74	33	0.8	0.1	0.7	3.1	3	360
BOU-DD26-0949	325.5	326.1	0.09	46	0.6	0.1	0.3	0.1	7	72
BOU-DD26-0949	332.3	336.0	3.04	57	3.7	0.3	0.1	0.0	4	356
Including	332.3	334.2	4.93	101	1.9	0.6	0.1	0.0	4	590
BOU-DD26-0949	341.7	342.5	0.66	16	0.8	0.1	0.1	0.2	2	84
BOU-DD26-0950	11.2	12.0	1.30	37	0.8	0.0	0.1	0.0	79	158
BOU-DD26-0950	19.0	34.1	1.70	98	15.1	0.0	0.6	1.7	64	299
Including	15.0	19.8	3.43	55	4.8	0.0	0.2	0.0	108	370
BOU-DD26-0951	35.5	38.0	1.27	153	2.5	0.1	0.4	1.1	100	304
BOU-DD26-0951	43.9	46.6	2.67	200	2.7	0.3	1.7	6.0	193	620
BOU-DD26-0951	49.6	54.0	0.35	54	4.4	0.0	1.7	2.8	573	186
BOU-DD26-0951	56.6	57.3	0.91	80	0.7	0.2	0.4	6.7	48	322
BOU-DD26-0952	44.5	46.0	0.65	14	1.5	0.0	0.1	0.1	3	77
BOU-DD26-0952	58.6	60.8	1.01	12	2.2	0.0	0.2	0.5	8	116
BOU-DD26-0952	63.7	64.6	0.55	25	0.9	0.0	0.5	2.2	24	129
BOU-DD26-0952	66.7	74.2	0.86	43	7.5	0.0	0.6	3.0	40	197
Including	72.1	74.2	1.52	89	2.1	0.1	0.9	4.5	59	340
BOU-DD26-0953	109.6	110.1	1.86	16	0.5	0.1	0.1	0.0	15	189
BOU-DD26-0953	112.8	114.5	1.21	15	1.7	0.1	0.1	0.1	13	135
BOU-DD26-0953	170.0	171.0	0.94	13	1.0	0.0	0.1	0.1	94	105
BOU-DD26-0954	72.8	74.6	2.75	45	1.8	0.1	0.1	1.1	13	321
BOU-DD26-0954	212.4	212.9	1.66	18	0.5	0.0	0.1	0.5	5	181
BOU-DD26-0954	225.0	225.8	1.01	18	0.8	0.0	0.3	0.5	5	126
BOU-DD26-0954	237.0	238.0	0.54	8	1.0	0.0	0.1	0.1	5	64
BOU-DD26-0954	239.7	240.2	0.51	36	0.5	0.1	0.8	2.2	2	149
BOU-DD26-0955	288.8	289.4	0.51	30	0.6	0.0	0.3	1.3	2	108
BOU-DD26-0955	291.4	292.8	0.67	7	1.4	0.0	0.2	0.4	4	80
BOU-DD26-0956	41.1	42.0	0.28	37	0.9	0.0	0.9	0.8	22	97
BOU-DD26-0956	70.1	70.6	0.48	33	0.5	0.0	0.3	0.6	3	95
BOU-DD26-0956	169.0	169.8	2.43	23	0.8	0.1	0.2	0.4	16	256
BOU-DD26-0956	178.0	180.3	0.77	10	2.3	0.1	0.0	0.1	9	88
BOU-DD26-0956	185.8	186.8	4.97	75	1.0	0.4	0.8	0.2	25	518
BOU-DD26-0956	184.0	189.5	1.80	20	5.5	0.1	0.2	0.2	17	197
BOU-DD26-0956	262.3	262.8	0.74	11	0.5	0.1	0.3	1.1	44	111
BOU-DD26-0956	286.9	287.4	1.09	8	0.5	0.0	0.2	0.7	8	125
BOU-DD26-0956	311.3	315.6	1.98	44	4.3	0.2	0.4	1.3	13	271
Including	311.3	312.2	5.84	39	0.9	0.1	0.4	0.6	15	590
BOU-DD26-0957	47.3	48.0	0.62	15	0.7	0.0	0.1	0.1	7	76
BOU-DD26-0957	77.5	78.0	0.61	97	0.5	0.0	0.6	0.3	9	171
BOU-DD26-0957	131.2	131.7	1.28	27	0.5	0.0	0.8	4.0	22	240
BOU-DD26-0957	151.0	151.9	0.03	80	0.9	0.0	0.0	0.1	2	84
BOU-DD26-0957	174.0	174.5	0.18	40	0.5	0.0	0.1	0.1	6	62
BOU-DD26-0957	177.0	178.5	0.69	32	1.5	0.0	0.9	2.1	6	156
BOU-DD26-0957	224.5	228.5	1.86	18	4.0	0.1	0.1	0.1	8	193
Including	227.3	228.5	4.52	33	1.2	0.2	0.0	0.0	21	452
BOU-DD26-0957	235.4	236.3	0.88	9	0.9	0.0	0.0	0.0	13	90
BOU-DD26-0957	271.0	272.3	0.79	9	1.3	0.1	0.0	0.0	14	86
BOU-DD26-0957	354.8	355.4	2.97	13	0.6	0.1	0.1	0.1	6	287
BOU-DD26-0957	360.0	361.0	0.66	2	1.0	0.0	0.0	0.1	4	64
BOU-DD26-0958	57.0	58.0	0.99	12	1.0	0.0	0.2	0.4	37	114
BOU-DD26-0958	141.8	148.0	1.45	15	6.2	0.1	0.1	0.1	9	157
BOU-DD26-0958	284.8	287.0	1.74	57	2.2	0.1	0.2	1.1	9	249
Including	284.8	285.7	3.38	120	0.9	0.3	0.2	0.6	13	459
BOU-DD26-0959	22.7	23.4	0.60	14	0.7	0.0	0.5	0.5	4	87
BOU-DD26-0959	136.0	137.0	0.83	10	1.0	0.0	0.4	0.5	7	103
BOU-DD26-0959	149.3	151.2	1.80	22	1.9	0.0	0.1	0.0	11	187
BOU-DD26-0959	158.9	159.4	1.98	36	0.5	0.1	0.1	0.8	10	241
BOU-DD26-0960	209.0	209.8	13.01	50	0.8	0.1	0.2	1.5	11	1,262
BOU-DD26-0960	216.4	216.9	6.49	52	0.5	0.0	1.4	0.2	14	667
BOU-DD26-0960	257.5	258.8	0.90	17	1.3	0.1	0.1	0.2	7	109
BOU-DD26-0960	279.2	280.1	0.24	33	0.9	0.0	2.1	0.8	5	110
BOU-DD26-0961	99.0	100.0	0.03	57	1.0	0.0	0.0	0.0	0	60
BOU-DD26-0961	188.5	189.2	0.64	33	0.7	0.1	0.4	0.3	15	112
BOU-DD26-0961	204.0	205.0	0.56	4	1.0	0.0	0.1	0.1	3	60
BOU-DD26-0961	249.2	249.7	0.71	9	0.5	0.0	0.1	0.0	12	77
BOU-DD26-0961	250.9	251.5	5.48	27	0.6	0.7	0.0	0.2	9	575
BOU-DD26-0961	261.4	262.8	0.14	41	1.4	0.0	0.1	0.0	9	57
BOU-DD26-0961	275.7	276.3	0.57	10	0.6	0.0	0.0	0.0	8	65
BOU-DD26-0961	278.3	294.4	1.51	14	16.1	0.1	0.0	0.0	8	156
Including	285.5	286.1	15.38	90	0.6	0.3	0.1	0.0	6	1,493
BOU-DD26-0961	298.0	299.0	0.16	128	1.0	0.0	0.2	0.5	3	158
BOU-DD26-0961	304.7	305.3	0.57	25	0.6	0.0	0.5	0.3	3	94
BOU-DD26-0961	308.0	308.6	0.36	20	0.6	0.0	0.2	0.3	3	63
BOU-DD26-0961	338.0	339.0	0.03	86	1.0	0.0	0.5	0.3	4	105
BOU-DD26-0961	377.0	378.0	0.03	54	1.0	0.0	0.0	0.1	0	60
BOU-DD26-0961	399.0	400.0	0.03	54	1.0	0.0	0.0	0.1	0	60
BOU-DD26-0961	418.0	419.0	1.49	17	1.0	0.2	0.0	0.0	9	169
BOU-DD26-0961	418.0	420.0	0.97	13	2.0	0.2	0.0	0.0	9	115
BOU-DD26-0961	425.0	432.9	0.94	19	7.9	0.2	0.2	0.1	10	123
Including	425.0	426.4	2.41	43	1.4	0.2	0.2	0.3	9	287
BOU-DD26-0962	49.8	50.4	1.35	62	0.6	0.1	1.3	6.5	12	345
BOU-DD26-0962	101.3	103.2	3.01	177	1.9	0.1	0.7	1.3	5	495
BOU-DD26-0962	105.9	106.8	0.52	7	0.9	0.0	0.1	0.0	13	59
BOU-DD26-0962	116.0	118.0	0.80	4	2.0	0.0	0.1	0.1	6	82
BOU-DD26-0962	121.0	123.0	0.75	7	2.0	0.0	0.1	0.4	2	88
BOU-DD26-0962	403.1	403.6	2.33	37	0.5	0.3	0.2	2.0	0	316
BOU-DD26-0963	101.0	102.0	0.59	2	1.0	0.0	0.0	0.1	2	57
BOU-DD26-0963	164.0	165.0	0.67	9	1.0	0.0	0.3	0.5	2	85
BOU-DD26-0963	309.4	310.9	0.92	6	1.5	0.0	0.2	0.5	3	103
BOU-DD26-0963	313.8	316.0	1.89	26	2.2	0.0	0.4	1.1	4	229
BOU-DD26-0963	328.3	331.1	2.14	43	2.8	0.2	0.3	0.7	7	267
Including	329.9	330.5	4.80	119	0.6	0.5	0.2	1.2	12	614
BOU-DD26-0963	350.0	352.3	3.44	39	2.3	0.1	0.1	0.5	8	367
BOU-DD26-0963	363.0	363.9	0.42	16	0.9	0.0	0.3	0.7	1	73
BOU-DD26-0964bis	283.8	285.0	0.51	12	1.2	0.2	0.1	0.5	11	83
BOU-DD26-0964bis	317.0	322.0	1.00	5	5.0	0.0	0.0	0.0	4	98
BOU-DD26-0964bis	335.0	336.0	0.51	29	1.0	0.0	0.3	1.0	19	102
BOU-DD26-0964bis	357.3	359.2	0.20	59	1.9	0.2	0.4	1.7	7	134
BOU-DD26-0964bis	360.8	361.4	0.27	62	0.6	0.2	0.4	0.6	23	117
BOU-DD26-0964bis	473.8	474.6	2.98	110	0.8	0.5	0.1	0.0	3	418
BOU-DD26-0965bis	387.0	388.0	0.41	18	1.0	0.0	0.1	0.0	6	59
BOU-DD26-0965bis	389.8	390.7	0.61	14	0.9	0.1	0.0	0.1	0	75
BOU-DD26-0965bis	411.0	412.8	1.65	13	1.8	0.1	0.0	0.5	2	178
BOU-DD26-0966	34.3	36.0	0.18	70	1.7	0.0	1.6	2.4	5	168
BOU-DD26-0966	101.0	101.5	2.23	14	0.5	0.0	0.2	0.7	5	234
BOU-DD26-0967	117.3	118.0	0.55	19	0.7	0.1	0.2	2.0	12	119
BOU-DD26-0967	121.7	122.3	0.16	42	0.6	0.0	0.2	0.2	16	67
BOU-DD26-0967	151.0	151.7	0.62	9	0.7	0.1	0.3	1.1	9	97
BOU-DD26-0967	196.4	197.3	0.96	1	0.9	0.0	0.2	0.3	7	98
BOU-DD26-0968	43.0	44.0	0.64	3	1.0	0.0	0.0	0.0	10	62
BOU-DD26-0968	125.5	126.0	2.62	14	0.5	0.1	0.2	0.2	9	262
BOU-DD26-0968	136.0	138.0	2.62	18	2.0	0.4	0.1	0.3	9	290
BOU-DD26-0968	171.2	174.6	2.57	61	3.4	0.2	0.1	0.0	11	311
Including	171.4	172.7	4.54	86	1.3	0.3	0.1	0.1	9	520
BOU-DD26-0968	180.0	181.0	1.58	15	1.0	0.0	0.7	0.8	18	188
BOU-DD26-0969	149.9	151.4	0.50	10	1.5	0.1	0.1	0.2	16	67
BOU-DD26-0969	162.6	164.0	0.93	14	1.4	0.0	0.0	0.0	23	99
BOU-DD26-0969	181.3	182.0	0.94	8	0.7	0.0	0.2	0.2	6	104
BOU-DD26-0969	190.0	190.9	0.79	30	0.9	0.0	0.2	0.3	7	112
BOU-DD26-0969	192.5	193.0	0.99	48	0.5	0.0	0.1	0.1	11	142
BOU-DD26-0969	196.7	199.1	1.82	23	2.4	0.0	0.4	0.1	10	198
BOU-DD26-0969	203.0	204.0	0.41	29	1.0	0.0	0.1	0.1	3	71
BOU-DD26-0969	207.4	218.0	2.37	29	10.6	0.1	0.1	0.3	8	260
Including	207.4	210.1	5.92	75	2.7	0.4	0.1	0.2	7	640
BOU-DD26-0969	245.1	245.6	0.39	19	0.5	0.0	0.4	1.8	16	102
BOU-DD26-0969	278.7	279.5	0.51	7	0.8	0.0	0.0	0.0	9	55
BOU-DD26-0969	281.2	282.0	0.99	9	0.8	0.0	0.1	0.1	6	102
BOU-DD26-0970	59.6	62.1	1.75	84	2.5	0.1	0.5	9.0	22	440
BOU-DD26-0970	210.6	211.1	1.01	17	0.5	0.1	0.0	0.0	8	115
BOU-DD26-0970	225.0	225.8	2.90	115	0.8	0.4	0.2	0.0	7	414
BOU-DD26-0970	234.0	234.7	0.42	11	0.7	0.0	0.0	0.0	5	53
BOU-DD26-0970	237.8	239.3	0.81	69	1.5	0.1	0.2	0.2	17	154
BOU-DD26-0970	246.4	248.5	2.30	21	2.1	0.2	0.1	0.1	14	243
BOU-DD26-0970	254.0	255.0	0.41	19	1.0	0.1	0.9	1.6	31	113
BOU-DD26-0970	278.2	279.0	0.68	20	0.8	0.1	1.4	1.6	8	145
BOU-DD26-0971	21.0	23.0	0.03	113	2.0	0.0	0.1	0.1	5	119
BOU-DD26-0971	27.0	28.0	0.03	59	1.0	0.0	0.1	0.3	4	68
BOU-DD26-0971	31.8	32.7	0.03	65	0.9	0.0	0.0	0.1	5	72
BOU-DD26-0971	34.5	35.0	0.94	125	0.5	0.1	0.7	0.3	15	237
BOU-DD26-0971	348.6	349.5	0.80	11	0.9	0.0	0.3	1.7	5	123
BOU-DD26-0971	353.1	354.3	0.67	19	1.2	0.0	0.2	0.8	3	102
BOU-DD26-0971	356.7	362.3	1.48	17	5.6	0.0	0.2	0.4	4	162
BOU-DD26-0971	368.0	369.0	0.96	18	1.0	0.0	0.3	0.8	5	127
BOU-DD26-0971	371.0	371.7	0.42	26	0.7	0.0	0.1	0.3	3	71
BOU-DD26-0971	372.7	373.5	0.34	33	0.8	0.0	0.2	1.4	3	98
BOU-DD26-0972	96.0	97.0	0.26	27	1.0	0.0	1.8	1.8	8	122
BOU-DD26-0972	186.9	187.8	0.57	0	0.9	0.0	0.1	0.2	5	58
BOU-DD26-0972	267.5	268.0	0.19	43	0.5	0.2	1.9	6.3	8	239
BOU-DD26-0972	269.8	274.2	2.24	53	4.4	0.2	0.0	0.3	9	276
Including	270.7	271.6	5.78	186	0.9	0.4	0.1	0.1	9	739
BOU-DD26-0972	300.3	301.5	14.97	79	1.2	0.1	0.1	0.6	9	1,447
BOU-DD26-0973	34.7	36.0	0.73	11	1.3	0.0	0.1	0.2	2	83
BOU-DD26-0973	54.0	59.0	1.34	8	5.0	0.0	0.1	0.8	5	147
BOU-DD26-0973	62.0	70.6	0.74	47	8.6	0.1	0.8	7.3	20	280
Including	65.9	69.0	1.14	88	3.1	0.1	1.8	17.3	25	585
BOU-DD26-0974	32.0	33.0	0.68	0	1.0	0.0	0.0	0.0	4	63
BOU-DD26-0974	37.0	38.0	0.70	54	1.0	0.0	2.4	2.0	9	205
BOU-DD26-0974	54.8	55.6	1.20	5	0.8	0.0	0.1	0.4	6	124
BOU-DD26-0974	116.0	117.0	0.03	88	1.0	0.1	0.2	0.1	6	106
BOU-DD26-0974	233.0	233.6	0.76	26	0.6	0.1	0.1	0.2	10	106
BOU-DD26-0974	251.6	252.3	0.61	10	0.7	0.1	0.1	0.1	8	72
BOU-DD26-0974	255.9	257.4	0.35	19	1.5	0.1	0.0	0.0	6	57
BOU-DD26-0974	259.0	260.5	0.54	23	1.5	0.0	0.1	0.1	14	79
BOU-DD26-0974	266.1	267.1	2.80	18	1.0	0.1	0.2	0.2	5	281
BOU-DD26-0974	275.1	279.0	2.90	44	3.9	0.2	0.4	0.3	9	333
BOU-DD26-0975	112.0	113.0	0.51	13	1.0	0.0	0.1	0.1	11	64
BOU-DD26-0975	154.4	155.0	0.33	39	0.6	0.0	0.3	1.1	18	98
BOU-DD26-0975	334.3	336.1	0.67	20	1.8	0.0	0.8	0.9	5	115
BOU-DD26-0975	368.0	368.5	0.34	25	0.5	0.0	0.4	0.8	5	80
BOU-DD26-0975	414.0	415.0	0.03	107	1.0	0.0	0.0	0.0	4	110
BOU-DD26-0976	118.8	119.5	0.40	15	0.7	0.0	0.1	0.1	45	57
BOU-DD26-0976	152.0	154.0	0.03	1,867	2.0	0.0	0.6	0.9	8	1,902
BOU-DD26-0976	243.7	244.3	0.53	9	0.6	0.1	0.1	0.2	7	68
BOU-DD26-0976	348.0	350.1	1.07	22	2.1	0.0	0.1	0.1	18	126
BOU-DD26-0977	0.0	354.0								NSR
BOU-DD26-0979	199.0	200.0	1.61	17	1.0	0.0	0.7	1.2	4	199
BOU-DD26-0979	221.0	226.5	3.55	64	5.5	0.1	0.3	0.1	21	397
Including	223.0	224.7	9.88	145	1.7	0.1	0.9	0.2	28	1,059
BOU-DD26-0979	273.0	276.3	3.67	29	3.3	0.0	0.1	0.1	20	364
Including	273.0	274.9	5.45	28	1.9	0.0	0.1	0.1	15	523
BOU-DD26-0979	280.9	282.7	1.19	26	1.8	0.0	0.1	0.0	14	137
BOU-DD26-0979	397.6	401.6	1.61	13	4.0	0.0	0.0	0.2	4	165
BOU-DD26-0981	4.0	6.0	0.03	77	2.0	0.0	0.0	0.1	3	81
BOU-DD26-0981	19.6	21.4	0.03	64	1.8	0.0	0.0	0.0	4	68
BOU-DD26-0981	277.7	278.7	0.30	27	1.0	0.0	1.2	1.4	9	108
BOU-DD26-0981	421.9	423.5	3.65	47	1.6	0.1	0.5	0.2	4	397
BOU-DD26-0982	386.5	391.2	0.78	18	4.7	0.0	0.3	0.3	7	102
BOU-DD26-0983	184.0	185.0	0.06	104	1.0	0.1	0.4	0.0	7	124
BOU-DD26-0983	283.8	285.2	1.80	8	1.4	0.0	0.1	0.0	9	173
BOU-DD26-0983	373.0	374.0	0.03	116	1.0	0.0	0.0	0.0	5	120
BOU-DD26-0983	423.4	424.3	0.74	6	0.9	0.0	0.0	0.0	14	75
BOU-DD26-0983	528.1	528.6	0.63	19	0.5	0.2	0.0	0.0	12	95
BOU-DD26-0983	532.0	532.5	0.77	443	0.5	0.1	2.8	0.4	10	576
BOU-DD26-0983	564.0	564.5	0.85	19	0.5	0.0	0.1	0.2	10	103
BOU-DD26-0983	571.0	572.8	0.95	14	1.8	0.0	0.0	0.0	8	103
BOU-DD26-0984	59.0	60.0	0.48	11	1.0	0.0	0.2	0.5	9	69
BOU-DD26-0984	81.0	81.5	0.46	23	0.5	0.0	0.2	0.3	10	77
BOU-DD26-0984	85.8	86.3	0.68	17	0.5	0.1	0.2	0.2	8	92
BOU-DD26-0984	113.9	114.5	1.29	21	0.6	0.2	1.1	1.6	8	203
BOU-DD26-0984	118.5	119.1	1.38	97	0.6	0.2	1.2	1.8	6	294
BOU-DD26-0984	122.4	126.0	0.72	53	3.6	0.2	1.6	2.6	5	219
BOU-DD26-0984	134.0	135.7	0.39	22	1.7	0.0	0.8	0.9	11	91
BOU-DD26-0984	142.0	143.0	0.03	61	1.0	0.0	5.9	4.8	15	273
BOU-DD26-0985	254.0	255.0	4.08	1	1.0	0.0	0.0	0.0	5	367
BOU-DD26-0985	333.9	334.4	0.55	5	0.5	0.0	0.2	0.2	5	64
BOU-DD26-0985	340.3	340.8	0.50	7	0.5	0.1	0.2	0.4	10	68
BOU-DD26-0985	394.0	395.0	1.66	0	1.0	0.0	0.0	0.0	5	150
BOU-DD26-0985	496.7	499.1	0.46	46	2.4	0.4	0.0	0.0	9	124
BOU-DD26-0986	96.1	96.8	0.62	19	0.7	0.0	0.5	0.4	5	94
BOU-DD26-0986	104.0	104.9	1.26	16	0.9	0.0	0.2	0.2	18	140
BOU-DD26-0986	132.8	136.4	1.50	50	3.6	0.0	0.5	2.1	12	238
BOU-DD26-0987	92.5	94.7	2.15	41	2.2	0.1	1.2	2.1	13	303
BOU-DD26-0988	97.7	98.4	0.77	59	0.7	0.1	1.3	8.1	10	322
BOU-DD26-0988	124.0	125.0	0.26	28	1.0	0.0	0.4	1.3	5	86
BOU-DD26-0988	386.0	387.0	3.20	3	1.0	0.0	0.0	0.1	5	293
BOU-DD26-0988	389.0	390.0	0.54	1	1.0	0.0	0.1	0.4	5	61
BOU-DD26-0989	99.1	99.6	0.82	19	0.5	0.1	0.1	0.1	9	102
BOU-DD26-0989	145.0	146.0	0.03	48	1.0	0.0	2.9	0.6	11	118
BOU-DD26-0989	176.8	179.8	1.05	38	3.0	0.2	1.2	1.9	11	210
BOU-DD26-0989	243.7	244.6	0.09	92	0.9	0.5	8.7	0.8	14	315
BOU-DD26-0989	246.4	250.8	0.32	38	4.4	0.1	2.2	1.4	11	139
BOU-DD26-0990	55.1	56.0	0.83	0	0.9	0.0	0.0	0.0	10	76
BOU-DD26-0990	143.9	144.4	2.01	128	0.5	0.3	0.7	3.8	20	421
BOU-DD26-0990	170.4	170.9	1.97	47	0.5	0.0	0.6	3.3	5	306
BOU-DD26-0991	188.0	189.0	0.03	76	1.0	0.1	5.0	3.4	7	245
BOU-DD26-0991	210.2	212.0	0.82	25	1.8	0.0	0.4	0.2	9	114
BOU-DD26-0991	300.0	300.8	0.17	38	0.8	0.1	1.8	2.6	23	150
BOU-DD26-0992	63.0	64.0	0.86	2	1.0	0.0	0.1	0.0	7	82
BOU-DD26-0992	67.0	69.0	2.22	18	2.0	0.0	0.1	0.3	14	226
BOU-DD26-0992	96.0	96.9	1.13	13	0.9	0.0	0.4	0.4	24	132
BOU-DD26-0992	181.6	182.1	2.09	37	0.5	0.1	0.3	1.1	11	257
BOU-DD26-0992	198.7	200.2	0.86	32	1.5	0.0	0.7	1.5	14	156
BOU-DD26-0993	54.0	55.0	0.03	109	1.0	0.0	0.0	0.0	3	112
BOU-DD26-0993	433.6	434.5	0.74	1	0.9	0.0	0.0	0.0	0	68
BOU-DD26-0996	73.6	75.5	1.71	5	1.9	0.0	0.1	0.5	5	170
BOU-DD26-0996	82.0	83.0	0.96	3	1.0	0.0	0.0	0.1	5	92
BOU-DD26-0996	193.4	194.1	0.50	6	0.7	0.0	0.1	0.4	5	62
BOU-DD26-0997	108.0	111.7	0.23	70	3.7	0.0	0.2	0.5	7	106
Including	108.0	109.8	0.03	118	1.8	0.0	0.1	0.2	7	127
BOU-DD26-0997	196.2	196.7	0.41	26	0.5	0.1	0.2	0.5	18	88
BOU-DD26-0997	317.0	318.0	1.43	36	1.0	0.2	0.7	1.4	10	220
BOU-DD26-0997	321.9	323.3	1.53	4	1.4	0.0	0.0	0.0	5	142
BOU-DD26-0997	326.1	326.6	2.07	1	0.5	0.0	0.0	0.0	6	188
BOU-DD26-0997	331.5	332.0	0.83	3	0.5	0.0	0.1	0.3	4	85
BOU-DD26-0997	335.7	336.2	0.65	0	0.5	0.0	0.0	0.1	5	61
BOU-DD26-0997	337.6	338.7	1.03	48	1.1	0.1	0.6	1.0	0	181
BOU-DD26-0997	343.4	344.9	0.43	41	1.5	0.0	0.9	0.6	5	111
BOU-DD26-0998	87.0	88.0	0.03	70	1.0	0.0	0.0	0.0	4	74
BOU-DD26-0998	452.4	454.1	2.70	38	1.7	0.1	0.3	0.1	4	294
BOU-DD26-0998	481.0	483.0	0.57	12	2.0	0.0	0.2	0.4	2	75
BOU-DD26-0998	488.0	490.1	0.63	32	2.1	0.0	0.3	0.8	1	113
BOU-DD26-0999	193.2	193.8	5.86	60	0.6	0.1	0.5	5.1	5	703
BOU-DD26-0999	198.4	199.4	1.91	27	1.0	0.1	0.7	1.5	1	249
BOU-DD26-0999	222.5	223.0	2.01	55	0.5	0.1	0.8	5.8	3	374
BOU-DD26-1000	48.0	49.7	0.63	15	1.7	0.0	0.7	0.8	114	104
BOU-DD26-1001	487.2	491.3	3.73	40	4.1	0.3	0.1	0.1	19	401
BOU-DD26-1002	64.0	65.0	0.03	358	1.0	0.0	0.0	0.0	2	361
BOU-DD26-1002	113.4	115.6	3.09	53	2.2	0.1	0.4	2.1	7	390
BOU-DD26-1002	139.2	140.0	0.67	57	0.8	0.1	0.8	3.1	2	202
BOU-DD26-1002	238.4	239.0	0.57	32	0.6	0.0	1.1	2.4	0	154
BOU-DD26-1003	15.1	15.7	1.50	4	0.6	0.0	0.1	0.1	10	143
BOU-DD26-1003	39.0	40.0	0.21	36	1.0	0.0	0.1	0.2	10	60
BOU-DD26-1003	131.0	132.0	0.61	0	1.0	0.0	0.1	0.0	5	56
BOU-DD26-1004	170.8	172.2	1.06	36	1.4	0.2	0.3	0.7	17	165
BOU-DD26-1004	233.0	233.8	0.70	26	0.8	0.0	0.6	0.8	5	120
BOU-DD26-1004	236.4	237.2	1.22	47	0.8	0.0	0.3	1.0	6	185
BOU-DD26-1004	242.5	243.8	0.86	64	1.3	0.0	0.2	0.4	5	155
BOU-DD26-1004	244.6	245.5	0.71	10	0.9	0.0	0.5	0.3	5	90
BOU-DD26-1004	250.5	252.5	2.70	86	2.0	0.1	0.6	0.8	6	364
BOU-DD26-1004	314.0	315.0	0.14	39	1.0	0.3	2.3	4.2	7	201
BOU-DD26-1004	347.0	348.0	1.54	0	1.0	0.0	0.0	0.0	7	139
BOU-DD26-1005	16.2	28.2	1.36	47	12.0	0.0	0.2	0.0	67	175
Including	16.2	18.5	3.61	100	2.3	0.0	0.2	0.0	138	431
BOU-DD26-1006	67.0	68.8	1.27	122	1.8	0.0	0.1	0.8	10	255
BOU-DD26-1006	153.6	155.0	0.74	12	1.4	0.2	0.4	0.1	8	103
BOU-DD26-1007	20.0	20.7	0.59	14	0.7	0.0	0.5	1.4	10	106
BOU-DD26-1007	22.2	22.7	0.35	28	0.5	0.0	2.0	5.2	10	205
BOU-DD26-1007	57.9	62.7	2.34	27	4.8	0.0	0.1	0.2	9	243
Including	57.9	59.7	4.75	43	1.8	0.0	0.1	0.4	13	482
BOU-DD26-1007	65.7	66.7	1.18	19	1.0	0.0	0.0	0.0	5	127
BOU-DD26-1007	104.9	108.6	1.35	58	3.7	0.0	0.0	0.4	5	190
Including	106.3	107.7	2.78	125	1.4	0.1	0.0	0.0	5	382
BOU-DD26-1007	129.6	132.0	0.45	22	2.4	0.0	0.5	0.7	6	86
BOU-DD26-1008	40.4	41.3	0.68	8	0.9	0.0	0.3	0.6	4	86
BOU-DD26-1008	107.8	112.0	2.47	130	4.2	0.1	0.1	0.4	4	369
BOU-DD26-1008	131.0	133.0	0.93	10	2.0	0.0	0.1	1.7	5	130
BOU-DD26-1009	75.9	77.7	2.50	37	1.8	0.0	0.2	0.1	5	268
BOU-DD26-1009	100.5	106.1	1.04	22	5.6	0.0	0.2	0.3	8	128
BOU-DD26-1009	139.2	140.1	0.01	57	0.9	0.1	0.2	0.2	5	74
BOU-DD26-1009	199.0	200.0	7.67	2	1.0	0.0	0.0	0.0	20	691
BOU-DD26-1009	311.0	312.0	0.40	53	1.0	0.0	1.2	1.3	10	140
BOU-DD26-1009	338.8	339.4	0.80	10	0.6	0.0	0.2	0.3	5	93
BOU-DD26-1009	340.8	341.3	1.86	26	0.5	0.1	0.1	0.1	5	203
BOU-DD26-1009	354.3	354.9	1.23	11	0.6	0.0	0.1	0.4	10	133
BOU-DD26-1009	440.0	441.0	0.00	60	1.0	0.0	0.0	0.0	10	61
BOU-DD26-1010	0.0	255.0								NSR
BOU-DD26-1011	30.6	33.4	3.16	43	2.8	0.0	0.6	0.5	10	351
BOU-DD26-1011	37.0	37.7	0.47	9	0.7	0.0	0.1	0.2	5	59
BOU-DD26-1011	39.5	40.0	1.80	23	0.5	0.0	0.3	0.3	30	198
BOU-DD26-1011	62.3	64.0	8.28	36	1.7	0.2	0.1	0.3	22	805
BOU-DD26-1011	276.7	277.2	0.55	53	0.5	0.1	0.7	3.0	5	181
BOU-DD26-1012	3.5	4.5	0.63	6	1.0	0.0	0.0	0.0	5	63
BOU-DD26-1012	15.0	17.0	0.75	23	2.0	0.0	0.0	0.0	8	90
BOU-DD26-1012	53.0	54.5	2.29	8	1.5	0.2	0.0	0.1	43	232
BOU-DD26-1012	67.4	68.4	0.60	36	1.0	0.6	0.2	0.7	10	151
BOU-DD26-1012	71.4	74.4	0.38	74	3.0	0.0	0.1	0.3	5	116
BOU-DD26-1013	290.9	291.5	3.87	106	0.6	0.2	0.4	0.2	49	477
BOU-DD26-1014	26.0	27.0	0.69	11	1.0	0.0	0.4	0.6	5	93
BOU-DD26-1014	37.9	43.6	0.42	18	5.7	0.0	0.8	1.1	10	95
BOU-DD26-1014	49.3	51.3	1.01	24	2.0	0.0	1.0	1.9	8	177
BOU-DD26-1014	73.5	74.0	0.64	18	0.5	0.0	0.5	1.1	10	108
BOU-DD26-1014	77.0	78.0	0.50	12	1.0	0.0	0.6	0.6	5	82
BOU-DD26-1014	129.0	130.0	0.74	4	1.0	0.1	0.0	0.6	5	88
BOU-DD26-1014	145.1	147.0	0.65	6	1.9	0.0	0.0	0.0	5	65
BOU-DD26-1014	178.0	179.0	0.68	7	1.0	0.0	0.1	0.1	5	73
BOU-DD26-1015	43.0	44.0	0.03	65	1.0	0.0	0.0	0.0	3	68
BOU-DD26-1015	83.0	84.0	0.16	59	1.0	0.0	1.0	1.5	43	124
BOU-DD26-1015	91.0	92.0	0.30	70	1.0	0.1	3.5	4.1	30	252
BOU-DD26-1015	98.5	99.0	0.71	112	0.5	0.0	2.5	10.8	2	445
BOU-DD26-1015	154.1	159.8	0.47	18	5.7	0.0	0.2	0.9	36	83
BOU-DD26-1015	171.2	171.9	0.03	96	0.7	0.1	3.8	2.6	9	227
BOU-DD26-1015	178.1	179.0	0.30	61	0.9	0.0	4.2	3.5	5	240
BOU-DD26-1016	20.6	21.7	0.23	41	1.1	0.0	1.9	1.7	10	135
BOU-DD26-1016	87.6	88.4	0.40	19	0.8	0.0	0.8	2.0	5	111
BOU-DD26-1016	98.8	99.3	0.43	29	0.5	0.0	1.3	1.5	10	124
BOU-DD26-1016	117.5	118.0	1.63	23	0.5	0.0	1.1	2.1	5	233
BOU-DD26-1016	128.0	129.0	0.05	99	1.0	0.0	0.1	0.1	10	109
BOU-DD26-1016	180.6	181.8	8.02	73	1.2	0.1	0.1	0.3	10	811
BOU-DD26-1016	185.2	186.6	3.04	120	1.4	0.1	0.5	0.8	7	426
BOU-DD26-1016	310.4	311.0	0.54	6	0.6	0.0	0.1	0.7	5	74
BOU-DD26-1016	367.3	368.1	1.17	20	0.8	0.1	0.6	0.7	10	157
BOU-DD26-1017	60.0	61.0	0.34	20	1.0	0.0	0.7	1.0	2	85
BOU-DD26-1017	87.5	88.4	0.58	12	0.9	0.0	0.8	1.4	0	108
BOU-DD26-1017	159.0	160.0	0.58	14	1.0	0.0	0.4	0.4	4	82
BOU-DD26-1017	186.0	186.6	0.27	43	0.6	0.1	1.0	5.5	6	207
BOU-DD26-1017	369.2	369.7	3.38	44	0.5	0.3	0.1	0.1	2	375
BOU-DD26-1018	106.4	110.0	0.62	17	3.6	0.0	0.8	1.5	13	120
BOU-DD26-1018	117.4	123.6	0.63	39	6.2	0.0	1.0	1.2	23	141
BOU-DD26-1018	136.9	147.0	2.26	20	10.1	0.0	0.7	0.5	13	248
Including	136.9	138.0	14.28	75	1.1	0.0	4.9	3.4	39	1523
BOU-DD26-1018	316.0	319.3	0.66	24	3.3	0.1	0.1	0.3	6	99
BOU-DD26-1019	137.3	138.7	0.35	30	1.4	0.0	0.1	0.1	26	68
BOU-DD26-1019	141.4	143.5	0.99	26	2.1	0.0	0.1	0.2	25	121
BOU-DD26-1019	177.0	177.6	0.93	26	0.6	0.0	0.1	0.0	15	112
BOU-DD26-1019	181.5	183.4	0.64	58	1.9	0.0	1.3	2.9	13	200
BOU-DD26-1019	184.3	185.2	0.48	18	0.9	0.0	0.1	0.1	15	65
BOU-DD26-1019	378.0	379.0	0.22	77	1.0	0.0	0.4	0.6	10	118
BOU-DD26-1019	382.0	386.0	0.42	26	4.0	0.2	0.8	1.5	42	122
BOU-DD26-1020	196.6	198.4	0.97	5	1.8	0.0	0.0	0.0	8	92
BOU-DD26-1020	203.8	205.5	1.01	20	1.7	0.0	0.3	0.5	7	126
BOU-DD26-1020	234.0	235.0	0.54	8	1.0	0.0	0.1	0.1	5	59
BOU-DD26-1020	362.5	363.4	0.78	10	0.9	0.0	0.2	0.3	5	89
BOU-DD26-1020	366.1	366.7	2.08	36	0.6	0.2	2.8	0.6	30	306
BOU-DD26-1020	369.4	370.3	1.12	5	0.9	0.0	0.2	0.3	10	117
BOU-DD26-1020	410.0	411.0	0.52	21	1.0	0.0	0.4	1.0	5	97
BOU-DD26-1020	435.5	436.1	0.39	72	0.6	0.1	1.1	0.5	5	142
BOU-DD26-1021	107.5	108.0	0.69	280	0.5	0.5	5.2	3.7	17	557
BOU-DD26-1021	179.9	184.3	1.76	12	4.4	0.1	0.2	0.3	4	184
Including	179.9	181.4	3.65	20	1.5	0.1	0.3	0.6	3	375
BOU-DD26-1021	211.0	211.8	0.03	65	0.8	0.1	0.2	0.1	5	81
BOU-DD26-1022	0.0	222.0								NSR
BOU-DD26-1023	0.0	150.0	0.00	0	150.0	0.0	0.0	0.0	0	0
BOU-DD26-1024	174.6	175.1	1.37	17	0.5	0.0	0.2	0.4	20	153
BOU-DD26-1024	187.0	187.5	0.54	7	0.5	0.0	0.3	1.8	10	100
BOU-DD26-1025	30.5	31.4	0.81	9	0.9	0.0	0.5	0.7	5	105
BOU-DD26-1025	35.0	38.0	1.79	25	3.0	0.1	0.1	0.4	6	199
BOU-DD26-1025	40.0	41.0	0.48	18	1.0	0.0	0.2	0.9	5	84
BOU-DD26-1025	86.4	87.8	1.40	23	1.4	0.0	0.1	2.0	5	195
BOU-DD26-1026	0.0	153.0								NSR
BOU-DD26-1027	131.8	132.4	0.53	35	0.6	0.1	2.2	1.9	3	166
BOU-DD26-1027	163.0	164.0	0.61	9	1.0	0.0	0.2	0.2	3	73
BOU-DD26-1027	247.0	247.8	1.69	25	0.8	0.2	0.0	0.7	5	206
BOU-DD26-1027	285.1	287.6	0.94	57	2.5	0.2	0.1	0.2	9	162
BOU-DD26-1027	343.6	344.1	0.81	10	0.5	0.0	0.4	1.1	5	113
BOU-DD26-1027	345.0	346.0	0.93	4	1.0	0.0	0.1	0.5	5	100
BOU-DD26-1028	288.3	288.9	0.74	10	0.6	0.0	0.6	2.9	10	148
BOU-DD26-1028	296.9	300.6	1.27	6	3.7	0.0	0.2	0.6	6	137
BOU-DD26-1028	305.2	306.2	9.23	11	1.0	0.0	0.1	0.1	5	844

* True width remains undetermined at this stage; all values are uncut.
** Ag equivalent is based on a silver price of US$30/oz with a process recovery of 96%, a gold price of US$2,800/oz with a process recovery of 96%, a zinc price of US$1.20/lb with a process recovery of 75%, a lead price of US$1.00/lb with a process recovery of 82%, and a copper price of US$4.60/lb with a process recovery of 75% resulting in the following ratios: 1g/t Au: 89.7g/t Ag; 1% Cu: 78.6 g/t Ag; 1% Pb: 18.7 g/t Ag; and 1% Zn: 20.4 g/t Ag

Appendix 2 – New Drillhole Coordinates of 2026 Boumadine Exploration Program (completed holes)

DDH No.	Easting	Northing	Elevation	Azimuth	Dip	Length (m)
BOU-DD26-0927	315361	3477854	1270	270	-50	201
BOU-DD26-0928	317203	3476200	1219	250	-50	267
BOU-DD26-0929	315742	3477962	1277	270	-50	588
BOU-DD26-0930	317053	3474526	1263	68	-50	621
BOU-DD26-0931	315786	3477961	1265	270	-50	489
BOU-DD26-0932	317019	3474514	1263	70	-51	576
BOU-DD26-0933	316993	3474551	1259	70	-50	540
BOU-DD26-0934	315283	3477646	1298	270	-50	105
BOU-DD26-0935	315657	3477854	1277	267	-51	399
BOU-DD26-0936	317243	3474701	1304	69	-51	210
BOU-DD26-0937	317203	3474679	1289	69	-50	255
BOU-DD26-0938	317249	3476217	1221	250	-49	321
BOU-DD26-0939	315689	3477857	1277	270	-50	501
BOU-DD26-0940	315325	3477646	1292	270	-50	162
BOU-DD26-0941	317172	3474664	1281	68	-50	213
BOU-DD26-0942	315363	3477646	1287	270	-50	205
BOU-DD26-0943	317291	3476235	1220	250	-49	361
BOU-DD26-0944	316958	3474592	1256	69	-50	585
BOU-DD26-0945	317160	3474852	1289	69	-50	234
BOU-DD26-0946	317135	3474736	1284	69	-51	60
BOU-DD26-0947	315738	3477857	1257	270	-50	375
BOU-DD26-0948	315776	3477857	1254	270	-50	417
BOU-DD26-0949	317328	3476247	1213	249	-49	354
BOU-DD26-0950	317080	3475172	1246	250	-49	114
BOU-DD26-0951	317095	3474831	1273	70	-50	57
BOU-DD26-0952	317118	3475180	1245	250	-50	156
BOU-DD26-0953	317203	3475206	1241	250	-50	258
BOU-DD26-0954	315403	3477649	1282	270	-50	276
BOU-DD26-0955	315449	3477648	1281	270	-50	330
BOU-DD26-0956	317280	3475235	1240	250	-49	375
BOU-DD26-0957	317316	3475247	1239	248	-50	399
BOU-DD26-0958	317239	3475221	1238	250	-50	327
BOU-DD26-0959	315484	3477650	1276	270	-50	402
BOU-DD26-0960	315530	3477645	1264	270	-50	351
BOU-DD26-0961	317364	3475264	1239	250	-50	474
BOU-DD26-0962	315830	3477960	1262	270	-50	459
BOU-DD26-0963	315626	3477647	1279	270	-50	426
BOU-DD26-0964	317408	3475277	1238	250	-51	45
BOU-DD26-0964bis	317407	3475276	1239	250	-51	528
BOU-DD26-0965	315665	3477646	1271	270	-50	30
BOU-DD26-0965bis	315665	3477645	1271	270	-51	465
BOU-DD26-0966	317096	3475278	1233	250	-50	174
BOU-DD26-0967	317134	3475293	1233	250	-50	228
BOU-DD26-0968	317172	3475307	1231	250	-50	225
BOU-DD26-0969	317207	3475322	1231	250	-50	288
BOU-DD26-0970	317243	3475335	1230	250	-50	405
BOU-DD26-0971	317362	3476258	1208	250	-50	402
BOU-DD26-0972	315586	3477646	1270	270	-50	402
BOU-DD26-0973	317058	3475265	1233	250	-50	111
BOU-DD26-0974	317276	3475347	1230	250	-50	300
BOU-DD26-0975	317324	3475361	1233	250	-50	417
BOU-DD26-0976	317360	3475373	1232	250	-50	432
BOU-DD26-0977	315700	3477645	1262	269	-50	354
BOU-DD26-0978	317398	3476273	1207	250	-49	106
BOU-DD26-0979	315551	3477756	1261	270	-50	428
BOU-DD26-0980	317398	3475382	1231	251	-49	33
BOU-DD26-0981	317438	3476287	1207	247	-52	501
BOU-DD26-0982	317401	3476274	1207	250	-51	452
BOU-DD26-0983	317440	3475398	1230	250	-50	600
BOU-DD26-0984	317045	3475400	1242	252	-50	240
BOU-DD26-0985	317400	3475383	1231	249	-50	507
BOU-DD26-0986	315330	3477544	1285	270	-50	165
BOU-DD26-0987	315291	3477544	1294	270	-50	108
BOU-DD26-0988	315737	3477643	1261	269	-50	411
BOU-DD26-0989	317087	3475413	1238	248	-50	255
BOU-DD26-0990	315370	3477545	1278	270	-50	210
BOU-DD26-0991	317127	3475426	1236	251	-50	360
BOU-DD26-0992	315409	3477544	1273	270	-50	252
BOU-DD26-0993	315635	3477754	1260	270	-50	451
BOU-DD26-0994	315710	3477755	1244	269	-50	51
BOU-DD26-0995	317162	3475438	1237	249	-50	141
BOU-DD26-0996	315710	3477755	1244	270	-50	507
BOU-DD26-0997	317206	3475456	1238	250	-50	453
BOU-DD26-0998	317478	3476302	1210	250	-50	505
BOU-DD26-0999	315497	3477544	1277	270	-50	351
BOU-DD26-1000	317235	3475071	1277	249	-50	207
BOU-DD26-1001	317523	3476317	1209	247	-53	602
BOU-DD26-1002	315449	3477544	1273	270	-50	303
BOU-DD26-1003	315281	3477803	1272	269	-50	141
BOU-DD26-1004	317164	3475438	1237	250	-50	423
BOU-DD26-1005	317148	3475035	1282	250	-50	114
BOU-DD26-1006	317269	3475084	1267	250	-49	216
BOU-DD26-1007	315363	3477805	1271	270	-50	153
BOU-DD26-1008	315403	3477805	1270	270	-50	204
BOU-DD26-1009	315602	3477545	1292	270	-50	453
BOU-DD26-1010	317301	3475092	1262	250	-50	255
BOU-DD26-1011	315546	3477543	1278	250	-50	402
BOU-DD26-1012	317185	3475049	1283	250	-51	150
BOU-DD26-1013	317323	3475102	1256	249	-50	306
BOU-DD26-1014	315448	3477804	1278	269	-50	360
BOU-DD26-1015	317354	3475110	1247	250	-50	309
BOU-DD26-1016	315489	3477804	1274	268	-50	412
BOU-DD26-1017	315523	3477806	1268	269	-50	450
BOU-DD26-1018	317393	3475126	1251	250	-50	369
BOU-DD26-1019	317437	3475142	1251	249	-49	402
BOU-DD26-1020	317486	3475161	1257	249	-50	471
BOU-DD26-1021	315750	3477548	1265	270	-50	450
BOU-DD26-1022	317158	3475195	1253	251	-50	222
BOU-DD26-1023	317020	3475492	1251	249	-50	150
BOU-DD26-1024	315799	3477546	1269	270	-50	450
BOU-DD26-1025	315320	3477802	1278	270	-50	153
BOU-DD26-1026	316989	3475479	1254	250	-49	153
BOU-DD26-1027	315557	3477807	1263	268	-49	381
BOU-DD26-1028	315598	3477807	1257	270	-50	402
BOU-DD26-1029	317439	3477693	1193	270	-50	411
BOU-DD26-1030	317786	3477695	1199	270	-50	404
BOU-DD26-1031	317054	3475506	1247	249	-49	204
BOU-DD26-1032	315684	3477801	1255	268	-50	306
BOU-DD26-1033	317127	3475533	1248	250	-50	318
BOU-DD26-1034	317168	3475547	1243	250	-50	351
BOU-DD26-1035	317208	3475562	1245	249	-49	411
BOU-DD26-1036	317251	3475577	1241	251	-50	471
BOU-DD26-1037	315840	3477545	1270	270	-50	450
BOU-DD26-1038	315879	3477548	1256	270	-50	351
BOU-DD26-1039	315730	3477804	1257	269	-50	354
BOU-DD26-1040	315772	3477802	1252	270	-50	402
BOU-DD26-1041	316430	3477654	1218	251	-50	231
BOU-DD26-1042	315641	3477806	1257	269	-50	453
BOU-DD26-1043	316470	3477667	1216	250	-50	285
BOU-DD26-1044	315924	3477549	1247	269	-50	411
BOU-DD26-1045	317913	3478095	1189	270	-50	401
BOU-DD26-1046	316512	3477682	1214	251	-50	333
BOU-DD26-1047	315285	3477697	1289	270	-50	102
BOU-DD26-1048	316552	3477696	1212	249	-51	375
BOU-DD26-1049	316593	3477710	1211	250	-50	426
BOU-DD26-1050	318116	3477693	1183	268	-51	397
BOU-DD26-1051	315321	3477694	1286	270	-50	162
BOU-DD26-1052	316633	3477723	1210	249	-51	480
BOU-DD26-1053	315968	3477550	1250	270	-50	483
BOU-DD26-1054	315356	3477694	1281	270	-50	204
BOU-DD26-1055	316675	3477738	1209	251	-49	549
BOU-DD26-1056	315398	3477697	1277	270	-50	258
BOU-DD26-1057	315445	3477697	1281	269	-50	327
BOU-DD26-1058	316713	3477753	1208	250	-50	501
BOU-DD26-1059	318453	3477694	1181	268	-51	401
BOU-DD26-1060	316751	3477764	1207	251	-49	528
BOU-DD26-1061	315485	3477697	1278	270	-50	429
BOU-DD26-1062	318265	3478102	1187	270	-48	21
BOU-DD26-1063	316014	3477552	1258	269	-50	451
BOU-DD26-1064	315530	3477700	1270	270	-50	477
BOU-DD26-1065	315577	3477697	1259	270	-50	555
BOU-DD26-1066	316795	3477780	1206	251	-50	564
BOU-DD26-1067	318264	3478097	1187	270	-50	404
BOU-DD26-1068	316841	3477803	1207	250	-50	603
BOU-DD26-1069	316497	3477567	1215	250	-50	107
BOU-DD26-1070	316885	3477815	1207	250	-51	705
BOU-DD26-1071	315628	3477693	1277	270	-50	414
BOU-DD26-1072	316539	3477581	1214	250	-50	152
BOU-DD26-1073	315736	3477701	1247	270	-50	360
BOU-DD26-1074	316479	3477615	1215	249	-49	108
BOU-DD26-1075	318603	3478100	1192	268	-51	401
BOU-DD26-1076	316579	3477599	1212	250	-50	200
BOU-DD26-1077	315307	3477459	1295	270	-50	108
BOU-DD26-1078	316562	3477645	1212	250	-50	240
BOU-DD26-1079	315340	3477460	1290	270	-50	168
BOU-DD26-1080	316650	3477678	1210	250	-50	351
BOU-DD26-1081	315665	3477700	1267	270	-50	450
BOU-DD26-1082	316621	3477616	1212	250	-50	251
BOU-DD26-1083	315705	3477696	1257	270	-50	525
BOU-DD26-1084	315390	3477462	1285	270	-50	204
BOU-DD26-1085	316773	3477723	1202	250	-50	450
BOU-DD26-1086	315424	3477462	1286	270	-50	252
BOU-DD26-1087	315480	3477461	1297	270	-48	339
BOU-DD26-1088	316660	3477634	1211	250	-50	311
BOU-DD26-1090	316737	3477663	1209	250	-50	378
BOU-DD26-1091	316515	3477520	1217	250	-50	105
BOU-DD26-1092	315518	3477464	1292	270	-50	378
BOU-DD26-1093	316774	3477676	1207	251	-50	405
BOU-DD26-1094	316586	3477546	1216	249	-49	192
BOU-DD26-1095	317459	3476353	1206	249	-53	491
BOU-DD26-1096	315562	3477463	1295	269	-50	426
BOU-DD26-1097	317498	3476366	1207	248	-52	503
BOU-DD26-1099	315607	3477464	1297	270	-50	501
BOU-DD26-1100	316665	3477578	1211	250	-49	282
BOU-DD26-1101	316808	3477686	1203	249	-49	459
BOU-DD26-1103	315692	3477461	1285	270	-50	516
BOU-DD26-1104	316854	3477698	1202	251	-49	504
BOU-DD26-1105	315734	3477461	1287	270	-50	288
BOU-DD26-1106	315652	3477461	1292	270	-50	510
BOU-DD26-1107	316820	3477739	1204	249	-55	606
BOU-DD26-1108	316741	3477606	1207	250	-50	354
BOU-DD26-1109	315780	3477459	1286	269	-50	303
BOU-DD26-1110	315818	3477462	1282	269	-50	354
BOU-DD26-1115	316894	3477711	1200	250	-50	552
BOU-DD26-1117	315384	3477358	1289	269	-50	195
BOU-DD26-1119	315475	3477362	1293	270	-50	312
BOU-DD26-1121	315562	3477354	1299	270	-50	405
BOU-DD26-1127	315687	3477354	1286	270	-50	414
BOU-DD26-1130	316546	3477480	1219	250	-50	105
BOU-DD26-1131	316580	3477493	1219	248	-50	174

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/5ca1cf6b-8695-44df-8032-07cdd9c4f264
https://www.globenewswire.com/NewsRoom/AttachmentNg/dd05ec0c-f353-4106-b676-a92b9b5d104c
https://www.globenewswire.com/NewsRoom/AttachmentNg/32400fab-b769-417a-83da-efd85055e5b1